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Abstract 
 
ELABORATION AND DESIGN OF α7 nAChR NEGATIVE ALLOSTERIC MODULATORS 
 
 
By Osama Ibrahim Alwassil, Ph.D. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2015 
 
Major Director: Małgorzata Dukat, Associate Professor, Department of Medicinal Chemistry 
 
α7 Neuronal nicotinic acetylcholine receptors are one of two major classes of receptors 
responsible for cholinergic neurotransmission in the central nervous system. The existence of α7 
neuronal nAChRs in different regions of the nervous system suggests their involvement in 
certain essential physiological functions as well as in disorders such as Alzheimer’s disease 
(AD), drug dependence, and depression. This project was aimed toward the discovery and 
development of small–molecule arylguanidines that modulate α7 nAChR function with improved 
subtype-selectivity through an allosteric approach. Identifying the required structural features of 
these small molecules allowed optimization of their negative allosteric modulator (NAM) actions 
at α7 neuronal nAChRs. MD-354 (3-chlorophenylguanidine) was the first small–molecule NAM 
at α7 nAChRs; however, it also binds at 5-HT3 receptors. The N-methyl analog of MD-354 
!appeared to be more selective toward α7 nAChRs than 5-HT3 receptors. Comparative studies 
using two series of novel compounds based on MD-354 and its N-methyl analog explored the 
aryl 3-position and investigated whether or not the MD-354 series and the N-methyl series bind 
in the same manner. Biological potencies of the MD-354 series and the N-methyl series of 
compounds, obtained from electrophysiological assays with Xenopus laevis oocytes expressing 
human α7 nAChRs in two-electrode voltage-clamp assays, showed that N-(3-iodophenyl)-N-
methylguanidine (28) is the most potent analog at α7 nAChRs. Our comparative study and 
Hansch analyses indicated different binding modes of the two series. 
In addition, we investigated: i) the length/size of the aliphatic side chain at the anilinic 
nitrogen, ii) the effect of alkylating the guanidine nitrogen atoms, and iii) the necessity of the 
presence of these nitrogen atoms for the inhibitory effects of arylguanidines at α7 nAChRs.  
In efforts to explain the varied functional activity of these arylguanidines, homology models 
of the extracellular domain and the transmembrane domain of human α7 nAChRs were 
developed, allosteric sites identified, and docking studies and hydropathic analysis conducted. 
The 3D quantitative structure-activity relationships for our compounds were also analyzed using 
CoMFA. A pharmacophore for arylguanidines as α7 nAChR NAMs was identified. 
Together, these data should be useful for the subsequent design of novel arylguanidine 
analogs for their potential treatment of neurological disorders. 
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I. Introduction 
 
 
 
In the human body, neurotransmitter receptors play a central role in cellular 
communication within various kinds of organs and tissues. They are vital proteins with a 
wide range of recognition capacity allowing them to process precise signal transduction, 
specifically in neurons. The localization and density of all neurotransmitter receptors on 
neuronal cells in the central nervous system (CNS) and the peripheral nervous system 
(PNS) are highly regulated.1,2 Generally, there are numerous types of receptors and, 
among them, only one superfamily of receptors, the ligand-gated ion channel (LGIC) 
superfamily, exhibits a significantly rapid role in the processing of chemical-to-electrical 
transduction during neuronal signaling.2 Cholinergic neurons are characterized by the 
storage, release, and stimulation of the neurotransmitter acetylcholine (ACh) in the CNS 
and PNS.2 At intercellular connections (i.e., synapses), the release of ACh from 
presynaptic neurons into the synaptic cleft initiates channel opening of nicotinic 
acetylcholine receptors (nAChRs), one of the most widely studied families of the LGIC 
receptors, in the postsynaptic region. This initiation of the open channel leads to the 
transfer of ions across the cell membrane and to depolarization at the motor endplate and 
subsequent stimulation of the targeted tissue. The family of nAChRs are part of the Cys-
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loop family of receptors, which were named because of the presence of a well-known 
disulfide bridge in their N-terminal domain within the superfamily of LGIC receptors. 
Neuronal nAChRs are the center of many extensive scientific investigations because 
of their involvement in numerous important neurophysiological pathways such as 
cognitive learning and memory, synaptic plasticity, and neuroprotection.3,4 In addition, 
nAChRs exist in discrete locations and are involved in distinct processes such as arousal, 
cerebral blood flow and metabolism, and inflammation. Also, nAChRs can be located 
presynaptically for the regulation of neurotransmitter release, and both pre- and 
postsynaptic nAChR expression is altered by numerous pathophysiological disorders. 
Among these disorders are two critical worldwide health problems of current interest that 
are believed to be mediated through nAChRs: i) dementia and ii) certain aspects of drug 
abuse. At the molecular level, however, there is little information about these receptors, 
and their gating mechanism (i.e., ligand affinity and selectivity, dynamics of channel 
activation/inactivation, ion specificity and conductance, and desensitization properties) is 
still poorly understood. 
i) Alzheimer’s disease (AD) is one of the most costly neuropsychiatric disorders, 
even when compared to other diseases such as stroke and heart disease. AD is a common 
form of dementia estimated to cause in all ages 5.3 million cases in 2015 in the US.5 
Among those, approximately 5.1 million Americans are age of 65 or older, and around 
200,000 Americans experienced early onset AD (i.e., under age 65). It is also estimated 
that an additional 3.5 million health care personnel will be needed by 2030 to preserve 
the present ratio of health care personnel to elderly Americans.5 Consequently, health 
care, extended term care and clinical expenses, are anticipated to drastically rise from 
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$203 billion in 2013 to an estimated $1.2 trillion by the year 2050.5 The available current 
therapies on the market are associated with severe side effects and do not effectively 
cover the problem of disease progression or improving patients’ quality of life.5 An 
optimal treatment should provide sufficient effectiveness to halt the progression of AD 
symptoms or even reverse the phases of this disease.  
ii) Drug of abuse (specifically marijuana abuse) is a problem that is estimated to 
cause around 1,243,000 cases seeking treatment per year in the United States.6,7 This 
number is more than the number of patients looking for treatment for cocaine or heroin 
use.6  
There are indications that agents that can antagonize the effects of ACh are of 
therapeutic value. There are two types of such agents: i) direct-acting antagonists (i.e., 
those that block the effect of ACh at orthosteric binding site), and ii) indirect-acting 
antagonists (i.e., those that act via an allosteric mechanism, such as negative allosteric 
modulators). Arylguanidines were identified in our laboratory as the first novel class of 
small–molecule negative allosteric modulators (NAMs) of α7 nAChRs (e.g., m-
chlorophenylguanidine mCPG; MD-354; IC50 = 7.98 µM).8 Because of a selectivity 
problem associated with  MD-354 (i.e., it also binds at 5-HT3 receptor),  we previously 
investigated arylguanidine structural components that are required for α7 nAChRs and 
that detract from 5-HT3 receptor binding.9 Here, we continue our previous investigation 
by examining different structural aspects of arylguanidines that are required for α7 
nAChR action using various medicinal chemistry approaches in order to develop novel 
analogs with an improved selectivity and inhibitory potency for α7 nAChRs.  
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As a powerful tool in medicinal chemistry, molecular modeling has proven to provide 
significant molecular insight into various bimolecular interactions. It would be instructive 
to examine the possible interaction site(s) and mechanisms by which small-molecule α7 
nAChR NAMs work. Since a crystal structure of the human α7 nACh receptor has not yet 
been determined, three-dimensional models of the extracellular domain (ECD) and the 
transmembrane domain (TMD) of human α7 nAChRs will be constructed in this work 
based on available nAChR crystal structures from different species. The results should 
allow, with certain caveats, for detailed insight about α7 nAChR allosteric sites and 
enhance the effort to develop novel small–molecule NAMs. 
The present investigation is aimed at understanding why and how arylguanidines 
work as NAMs of ACh action at α7 nACh receptors. 
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II. Background 
 
 
 
A. Cholinergic Receptors 
 
In the CNS, cholinergic neuronal networks might represent the most important 
neuromodulatory neurotransmitter system.2,10 This cholinergic system is widely 
distributed and exists in both projection neurons and interneurons.11,12 The primary 
function of these neurons is to control activities that depend on selective attention, and to 
regulate higher cognitive functions such as memory and learning.2 Two major pathways 
that are considered the sources of the cholinergic system are the basal-forebrain 
cholinergic neurons and the pedunculopontine–lateral dorsal tegmental neurons where 
they project by widespread innervation to almost every area of the brain (Figure 1).13,14 In 
addition, cholinergic interneurons exist in multiple brain regions such as the striatum and 
neocortex where they provide innervation for nearby neurons.15,16 Both types of 
cholinergic neurons originate from the laterodorsal tegmental nucleus (LDT) or 
pedunculopontine tegmental nucleus (PPT), and cholinergic interneurons in the striatum 
regulate the mesolimbic dopamine system through acetylcholine receptors (AChRs) 
expressed on multiple neuronal populations within the system (e.g., dopaminergic 
neurons).15,16 
!! 6!
 
 
 
 
 
Nicotinic acetylcholine receptors (nAChRs) are one of two major classes of receptors 
responsible for cholinergic neurotransmission in the central nervous system (CNS).18 
Cholinergic neurotransmission first requires the assembly of the neurochemical mediator, 
acetylcholine (ACh), by the synthetic effect of choline acetyltransferase (CAT) in 
presynaptic cholinergic neurons. The neurotransmitter ACh interacts with nAChRs as 
well as with the other class of receptors in the cholinergic system, muscarinic 
acetylcholine receptors (mAChRs).18 While mAChRs are metabotropic G-protein-
Figure 1. A representative structure of mammalian brain containing the sources and 
the major pathways of cholinergic neuronal projections (i.e., basal-forebrain 
cholinergic neurons and pedunculopontine–lateral dorsal tegmental neurons) (adapted 
from Felten and Shetty).17
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coupled receptors (GPCRs) that produce excitatory or inhibitory responses, nAChRs are 
ligand-gated ion channel receptors (LGICRs) in which the excitatory response is 
achieved by increased cellular sodium (Na+) and calcium (Ca2+) levels.18 
Nicotinic AChRs are highly expressed in human brain in the synaptic region and 
other extrasynaptic locations.19 In the synapse, presynaptic nAChRs regulate 
neurotransmitter release whereas postsynaptic nAChRs allow the excitatory transmission 
process.19 Extrasynaptic nAChRs influence many neurotransmitter systems by mediating 
intracellular signals as well as neuronal excitability.19 
Nicotinic AChRs are members of the Cys-loop family of LGICRs.20 Members of the 
Cys-loop receptor family are formed by the assembly of five identical (homomeric) or 
different (heteromeric) subunits (i.e., pentamers).20,21 Each subunit consists of three main 
domains (Figure 2): a large extracellular N-terminal domain (ECD), four transmembrane-
spanning helices (i.e., the transmembrane domain (TMD), M1–M4), and an intracellular 
domain (ICD).20,21 The ECD consists of 10 β-strands and the loops connecting them. The 
sixth and the seventh β-strands are constrained by a disulfide bond connecting two highly 
conserved cysteine residues. This highly conserved Cys-Cys bridge is what gives the 
family its name.20  
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Figure 2. Structural representation of a nAChR model. (A) A whole receptor 
representation including the three main domains obtained from PDB (PDB ID: 2BG9); 
the ECD, the TMD domain, and the ICD. (B) A top view of five different colored 
subunits forming the receptor. (C) The orthosteric binding site formed by loops 
located at the interface between the two subunits; the principal subunit ribbon colors: 
red, loop A; blue, loop B; yellow, loop C; the complementary subunit ribbon colors: 
green, loop D; orange, loop E; purple, loop F.  
α7!
α7!
α7!
α7!
α7!
(B) 
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Generally, nAChRs can be divided, based on subunit composition, into two general 
types, neuronal nAChRs (NnAChRs) and muscle-type nAChRs (MnAChRs).22 
Considering the seventeen nAChR subunits of vertebrate species that have been 
identified (i.e., α1- α10, β1-β4, γ, δ and ε), various families of nAChR subtypes can be 
formed by different subunit combinations.23 All of these subunits are present in humans 
as well as in other mammalian species except α8 that exists only in avian species. The 
muscle-type nAChRs are composed of two α1 subunits as well as β1, γ, and δ subunits. 
The latter is replaced by ε subunits in the adult-neuromuscular junction of vertebrates.24 
Conversely, isoforms that form the neuronal-type of nAChRs are composed of certain 
subunits (i.e., α2-7, 9, 10; β2-4) and can exist as heteropentamers (e.g., α4β2) or, 
sometimes, as homopentamers (e.g., α7, Figure 2). The α4β2 receptors are the major 
population of nAChRs in mammalian brain; the α7 receptor subtype is considered the 
second most abundant nAChR in the central nervous system.23 On the other hand, a 
common heteromeric nAChR (i.e., α3β4) represents the most abundant type of nAChR in 
autonomic ganglia, adrenal medulla, and in the dorsal medulla, pineal gland, medial 
habenula, nucleus interpeduncularis, and retina.23,25  
Although α7 nACh receptors are well-known to be cation-permeable (Na+ and Ca2+) 
homopentamers,18 there is also emerging evidence that α7 nAChRs can form 
functionally-active heteropentamers with β-subunits.26,27 The binding site of the 
endogenous ligand ACh (i.e., the orthosteric site) is located at the interface of ECDs of 
every two adjacent subunits in homomeric receptors.25 Upon agonist binding, α7 nAChRs 
are characterized by extremely fast activation (<5 milliseconds (ms)) and rapid 
desensitization (<100 ms).25 The α7 nAChRs are also known, among other nAChR 
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subtypes, by their high permeability to calcium, thus triggering a series of intracellular 
calcium-dependent systems.19 
As will be discussed in a subsequent section, α7 nAChR ligands are viable 
therapeutic agents, however, there is a lack of commonly available selective α7 nAChR 
competitive agonists and classical antagonists (i.e., competitive antagonists).24 However, 
current attempts in the development of α7 nAChR-selective ligands are confronted with a 
considerably high sequence homology of the orthosteric binding sites among nAChR 
subtypes.28,29 The lack of subtype-selectivity for nAChR drugs often leads to multiple 
cholinergic side effects and thus prevents them from being used as therapeutic agents. 
Furthermore, the limited availability of nAChR-selective ligands has hindered progress 
toward a complete understanding of the essential functions of different nAChR 
subtypes.29 
Competitive antagonists, by definition, maintain the inactive state of receptors. To 
understand the deactivation process caused by α7 nAChR competitive antagonists, 
Monod, Wyman, and Changeux proposed a model (i.e., the MWC model) explaining the 
nature of protein allosteric transitions.30,31 Receptors are dynamic structures that can exist 
in different states (i.e., distinct functional conformations). For α7 nAChRs, four different 
states are possible under normal conditions (Figure 3). The binding of α7 nAChR 
competitive antagonists shifts the equilibrium and stabilizes the receptor‘s conformation 
to the inhibition/desensitization state.32 
 
!
!! 11!
!
 
 
 
 
Figure 3. Different nAChR conformations according to the MWC model that explain 
the allosteric nature of the receptor: the resting state (R), the active state (A), the fast-
onset desensitized state (I), and the slow-onset desensitized state (D). Adapted from a 
review by Jensen et al.24 
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B. α7 nAChR Agonists 
 
Naturally-occurring alkaloids represent an old class of nonselective and high-affinity 
agonists for nAChRs. Compounds such as  (-)-nicotine (1), (-)-lobeline (LOB; 2) and (±)-
epibatidine (EPI; 3) (Figure 4) are some members of this class that have been extensively 
investigated to understand their molecular role in activating nAChRs.24,33,34 The 
selectivity of agonists for α4β2 and α7 nAChRs was found to be highly dependent on the 
local binding forces and the long-range electrostatic interactions between the protonated 
portion or the cationic part of the agonist structures and the receptors.35 For example, a 
conformationally restricted analog of ACh (i.e., 4; Figure 4), is a highly selective full 
agonist at the α7 nAChRs (Ki = 92 nM) over α4β2 nAChRs (Ki = 16,000 nM).35 Detailed 
information of ligand-receptor attractive forces could guide the design for novel, highly 
selective agonists targeting nAChR subtypes.34 
An important focus of medicinal chemistry studies in the field of nAChRs was on a 
series of novel compounds derived from the nicotine (1) and epibatidine (3) skeletons. 
For example, substitution of the pyrrolidine ring of nicotine with an 
azabicyclo[3.2.2]nonane ring (i.e., TC-1698; 5) (Figure 4) resulted in a compound with 
full agonist activity at α7 nAChRs (EC50 = 0.44 µM) with insignificant activities at other 
nAChR subtypes.24 However, the synthesis of novel α7 nAChR agonists still faces a 
selectivity challenge due to the well-known cross-activity with 5-HT3 receptors.24 This 
cross-activity results from the high homology in the orthosteric site between the two 
receptor  types.  The 5-HT3 receptor  antagonist  tropisetron (6)  (Figure 4),  for  instance,  
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Figure 4. The chemical structures of selective and nonselective α7 nAChR agonists: (-
)nicotine (1), (-)lobeline (LOB; 2), (±)epibatidine (EPI; 3), ACh-restricted analog (4), 
TC-1698 (5), tropisetron (6), PNU-282987 (7), and GTS-21 (8). 
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acts as a partial agonist at α7 nAChRs (EC50 = 0.38 µM).24 Tropisetron has higher 
binding affinities (more than 1000-fold) at 5-HT3 and at α7 nACh receptors than at α4β2 
and muscle-type nAChRs; however, tropisetron is not selective for the α7 nAChRs since 
it antagonizes α3β4 nAChR signaling.24 Nevertheless, a new generation of quinuclidine 
analogs, such as the p-chlorobenzamide analog PNU-282987 (7), are highly selective α7 
nAChR agonists (EC50 = ~3 µM).24 Moreover, the anabaseine analog GTS-21 (8) is 
considered the prototypical selective partial agonist of the α7 nAChRs (EC50 = 6 µM).24 
The ACh precursor and metabolic product, choline, produces selective-full agonist 
activity at α7 nAChRs (EC50 = ~1000 µM).24,34 
 
C. α7 nAChR Antagonists 
 
Antagonists of α7 nAChRs are represented by a large group of structurally 
heterogeneous compounds, and most have been obtained from natural sources. The need 
for α7 nAChR antagonists is highly appreciated in animal studies and tissue cultures. 
Potent and selective α7 nAChR antagonists can provide optimal settings to precise 
detection of different receptor-effects in multiple receptor systems. Several naturally 
occurring toxins represent ideal examples of compounds antagonizing ACh at α7 
nAChRs. Furthermore, the inhibitory activity of some drugs on α7 nAChRs was 
identified as an adjuvant effect of their main pharmacological effect.  
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1. Competitive Antagonists 
 
1. Peptides 
Although several peptides were identified as antagonists for nAChRs, the majority of 
these toxins show inhibition in all subtypes of neuronal nAChRs.36 For example, 
neosurugatoxin and lophotoxin are two peptides recognized as non-selective nAChR 
inhibitors. There is, however, a minor group of peptides that show selectivity toward α7 
nAChR binding. The two particular peptides best-known to selectively antagonize α7 
nAChRs are: α-Conotoxin, a peptide that belongs to the conotoxin group that is known to 
be a cysteine-rich peptide extracted from cone snails (Conus pennaceus),37 and α-
bungarotoxin,38,39 a venom that is extracted from the Taiwanese krait Bungarus 
multicinctus. Although these two groups of peptides are highly specific to nAChRs, their 
interactions with the receptors are irreversible.39 This significant binding property has 
been exploited in the standardization of experimental procedures to isolate nAChRs from 
the electric organs of the marine ray Torpedo.38,40 Consequently, extensive knowledge of 
the diversity and molecular properties of receptors have been identified due to 
developments in molecular biology techniques.  
Due to their size and physicochemical properties, both α-conotoxin and α-
bungarotoxin do not pass biological barriers such as the gastrointestinal (GI) tract and 
blood–brain barrier (BBB).41 The structures of these peptides lack drug-like properties, 
and this limits their use as therapeutic agents. The disadvantages of peptides has led to an 
effort to identify alternative small molecules that have better pharmacokinetic features 
(i.e., absorption, distribution, metabolism and elimination (ADME)) in humans.42 
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2. Methyllycaconitine 
 
Methyllycaconitine (MLA; 9) (Figure 5) is a naturally occurring norditerpenoid 
alkaloid isolated from the Delphinium and Consolida species.43 MLA is a competitive 
antagonist for α7 nAChRs (IC50 = 0.0017 µM) and is the standard α7 nAChR antagonist 
in pharmacological studies.24,44 The binding of MLA is relatively selective for α7 
nAChRs (Ki value of 5-10 nM), although it possesses moderate binding affinity for α3β4 
and α4β2 nAChRs (Ki value of around 1,300 nM).24,38 
The therapeutic utility of MLA is limited because of its large molecular mass and 
narrow therapeutic index.45 Thus, the typical use of MLA is as an experimental tool for 
investigating the pharmacological properties and the heterogeneity of nAChRs. In 
binding studies, the sensitivity to low nanomolar concentrations of [3H]MLA has been 
interpreted as an indication for the presence of α7 nAChRs.46,47 Other pharmacological 
experiments indicate that, when MLA potently inhibits presynaptic nAChRs, it blocks the 
mediation of [3H]dopamine release from striatal synaptosome sites.43,47 Furthermore, 
MLA has been utilized as a lead compound for the identification of novel nAChR 
antagonists, considering the structural components of MLA that might produce favorable 
features for the newly proposed nAChR ligands.48,49 
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3. Memantine 
 
Memantine (10; Figure 5) is a low molecular-weight drug, presently approved by the 
Food and Drug Administration (FDA) for symptomatic treatment of moderate-to-severe 
AD. The approval of this drug is based on its ability to noncompetitively antagonize 
NMDA receptors.38,50 Beside this pharmacological action, memantine was shown to be 
an α7 nAChR antagonist (IC50 = 0.34 µM). While some50 consider the effect on α7 
nAChRs as an undesired property that might worsen the condition of AD patients, 
Banerjee et al.51 considered this inhibitory activity as an advantageous action. However, 
Figure 5. The chemical structures of selective and nonselective α7 nAChR 
antagonists: methyllycaconitine (MLA; 9) and memantine (10), respectively. 
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more experiments are needed to clarify the significance of memantine’s inhibitory 
activity on α7 nAChRs for AD. In any event, memantine certainly cannot be considered 
as an α7-selective agent. 
 
2. Non-Competitive Antagonists 
 
Non-competitive antagonists (NCAs) are a class of compounds that inhibit the 
activity of receptors by interacting with sites distinct from the agonist’s binding site, and 
therefore do not compete with agonists for binding. Since the action of NCAs is not 
surmountable by agonist, there are two possible mechanisms by which NCAs can exert 
their activity on nAChRs. The first possible mechanism is through direct blockade of the 
receptor’s channel (i.e., channel blockers). Channel blockers are characterized, 
pharmacologically, by blocking the receptor’s currents in a voltage-dependent manner.52 
On the other hand, NCAs can inhibit the receptor activity in a voltage-independent 
manner (i.e., negative allosteric modulators (NAMs); discussed in the next section).52 
NAMs exert their activity on nAChRs without blocking the receptor’s channel.  
A typical example of an NCA for neuronal nAChRs is the synthetic compound 
mecamylamine (11; Figure 6).52,53 Mecamylamine blocks the ion-channel of most 
neuronal nAChRs with more sensitivity toward α/β heteromers than α7 nAChRs, which 
requires 10 µM for full blockade.53 Another example of channel blockers of α7 nAChRs 
is naltrexone (12; Figure 6) (IC50 ~ 25 µM).
54 In addition to its opioid antagonist activity, 
naltrexone shows a voltage-dependence effect on the α7 nACh receptor currents.54  
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D. Positive Allosteric Modulators 
 
Allosteric modulators are those ligands that interact with the receptor’s allosteric sites 
and modify either or both the binding and the signaling of the orthosteric ligand. 
Allosteric modulators have no intrinsic channel activation properties and, thus, their 
pharmacological function is to modify normal receptor mechanisms.55 Both type of 
allosteric modulators (i.e., positive allosteric modulators or PAMs, and negative allosteric 
modulators or NAMs) are believed to alter the energy barriers for state transitions and/or 
stabilize the relative energy levels of particular receptor states.55,56 Consequently, 
modulation of receptor activity involves not only the stabilization of channel 
opening/closing states but also the kinetics of activation, deactivation, desensitization, or 
resensitization (Figure 3).  
Figure 6. The chemical structures of two channel blockers of α7 nAChRs: 
mecamylamine (11) and naltrexone (12). 
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Once an agonist associates with the receptor, it induces a conformational transition 
(Figure 3) from a resting state (channel closed) to an activated state (channel open).57 For 
α7 nAChRs, a conformational transition to a desensitized state (channel closed) is 
expected in less than one second, if the agonist remains bound. In order for the receptor 
to return to the resting state, the agonist must dissociate.57 The variety of structures of α7 
nAChR allosteric modulators alter this system with mechanistically distinguishable 
modes that, eventually, can be observed in the different forms of the agonist-evoked 
inward currents.57,58  
Based on the pharmacological profiles of structurally distinct α7 nAChR modulators, 
two types are recognized.59 Type I PAMs predominantly increase agonist response 
amplitude without significant effect on response decay rate. Type II PAMs enhance 
response amplitude and also reduce receptor desensitization, allowing fast reactivation 
from the desensitized state. Given the intricacies of LGIC states and kinetics, it should be 
anticipated that more than one mechanism could underlie the broad modulator categories 
identified to date.57 In addition to these two types, some identified PAMs display 
exceptional properties that are intermediate between the type I and type II classes.57-59  
The definition of an allosteric modulator for α7 nAChRs is also applicable to 
polypeptides that have been found to significantly enhance the ACh-evoked currents. The 
Ly-6/uPAR related protein 1 SLURP-1 (secreted by human keratinocytes) and the C 
terminus peptide fragment of acetylcholinesterase (AChE) are found to be highly 
selective PAMs at the human α7 nAChRs.60,61 However, because of their size and 
physicochemical properties, these agents cannot cross the blood brain barrier and are not 
useful as for exploring their pharmacological actions for in vivo studies.62 This issue 
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signifies that the development of small molecule modulators is a promising approach in 
medicinal chemistry.  
 
 
1. Extracellular Domain (ECD) PAMs 
 
i. Galantamine 
 
Galantamine (Gal; 13) (Figure 7), an alkaloid originally isolated from snowdrop 
flowers, is an FDA-approved drug for symptomatic treatment of mild-to-moderate AD 
and has been also tested as an adjuvant therapy to improve cognitive function in 
schizophrenia.63-65 The approval of this drug is based on its ability to inhibit the 
cholinesterase enzyme, which is responsible for the breakdown of ACh. Besides this 
pharmacological action, galantamine was shown to have a synergistic effect at α7 
nAChRs through an allosteric-modulating mechanism.66,67 Galantamine is considered a 
type I PAM since it does not affect the desensitization time of α7 nAChRs.24,55 
The location at which galantamine binds on α7 nAChRs has been extensively 
investigated using photoaffinity labeling, epitope mapping studies with the monoclonal 
antibody (mAb) FK1, and site-directed mutagenesis studies.68-70 These studies identified 
the location of the binding site to be at the outer surface of the ECD, in an area that 
overlapped with the ACh site. Three amino acid residues (i.e., Val196, Thr197, and 
Phe198) located on β-strand 10 of the α7 subunit can weaken galantamine binding after 
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mutation. From these three residues, only Thr197 appeared to be an essential attachment 
point since its mutation influenced binding the most.70 
 
ii. Physostigmine 
 
 Like galantamine, physostigmine (14; Figure 7) shows a dual mode of action, as a 
cholinesterase inhibitor (AChEI) and PAM.68,69 Historically, physostigmine showed the 
ability to enhance memory in normal individuals as well as in patients suffering 
dementia.71 However, the very short half-life of physostigmine (t1/2 ~ 30 min) limited its 
use as a memory protective agent.72 Currently, the FDA-approved use of physostigmine 
is to reverse the anticholinergic effects of toxic doses of cholinergic drugs.  
The binding site location of physostigmine at α7 nAChRs was identified using 
epitope mapping studies with the FK1 monoclonal antibody and photoaffinity labeling 
studies with physostigmine.68-70 Furthermore, physostigmine binding was blocked by the 
mAb FK1 which indicates the same general area as the galantamine binding site.69 
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Figure 7. The chemical structures of PAMs of α7 nAChRs: galantamine (13), 
physostigmine (14), PNU-120596 (15), and ivermectin (16). 
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2. Transmembrane Domain (TMD) PAMs 
 
a. PNU-120596 
 
1-(5-Chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea or PNU-120596 
(15; Figure 7) is an α7 nAChR PAM that was originally discovered by high-throughput 
screening.73 PNU-120596 is considered a type II PAM since it has the ability to enhance 
peak ACh-evoked currents and slow the response decay rates in cells expressing α7 
nACh receptors.73 Moreover, there is a remarkable selectivity of PNU-120596 for α7 
nAChRs with no significant effect on most other subtypes of nACh receptors.73  
Many efforts targeting the identification of the exact binding site for PNU-120596 at 
α7 nAChRs have been reported.  Evidence shows that the intrasubunit cavity in the TMD 
of α7 nAChRs is the potential location for the PNU-120596 interaction.74,75 Furthermore, 
mutagenesis studies indicate that the amino acids Ser222 and Ala225 from M1, Met253 
from M2, and Phe455 and Cys459 from M4 have essential attachment points with  PNU-
120596.74  
 
b. Ivermectin 
 
Ivermectin (16; Figure 7) is a macrocyclic lactone derivative of a natural compound 
that can be isolated by fermentation of the soil microorganism Streptomyces avermitilis.76 
Ivermectin is available in the market as an antiparasitic agent in both human and 
veterinary medicine.77 The antiparasitic effect of ivermectin is believed to result from its 
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agonist activity on glutamate-gated chloride channels as the major target.78 Additional 
biological targets of ivermectin include the modulation of multiple LGICR actions such 
as its positive modulatory activity on human α7 nAChRs.79 Unlike PNU-120596, 
ivermectin modulation is considered as a type I PAM. 
Ivermectin, however, shares a similarity with PNU-120596, in that mutagenesis 
studies indicated the potential location for ivermectin interaction at α7 nAChRs to be at 
the large intrasubunit cavity in the TMD.80 Moreover, the amino acids Ala225 from M1, 
Gln272 from M3, and Thr456 and Cys459 from M4 have essential attachment points with  
ivermectin.80 Interestingly, mutations of three amino acids (S222M, M253L and S276V) 
were able to convert ivermectin from a PAM into a NAM.80  
 
 
E. Negative Allosteric Modulators 
 
Another approach to inhibiting the action of ACh at α7 nAChRs is to identify an 
allosteric modulator that selectively deactivates the receptors (i.e., negative allosteric 
modulators (NAMs)). As described previously, allosteric modulators are receptor ligands 
that interact with sites distinct (i.e., allosteric sites) from the orthosteric site and mediate 
either or both the binding and the signaling of the orthosteric ligand.25 The mechanism of 
allosteric modulations has been extensively studied and was clinically initiated by the 
binding of benzodiazepines at the allosteric binding site of GABAA receptors.81 For α7 
nAChRs, allosteric modulators tune up (i.e., PAMs) or tune down (i.e., NAMs) receptor 
activity when the endogenous neurotransmitter ACh is present.82 NAMs are different 
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from classical antagonists where direct binding to the orthosteric site and a continuous 
effect occurs, regardless of normal neuronal activity. Allosteric modulators have unique 
advantages, such as the saturability of the allosteric site, which provides better control 
over the administered agent.82,83 While classical agonists and antagonists can cause 
extreme stimulation or inhibition of the receptor, an allosteric modulator has a maximal 
ceiling.83 This advantage reduces any undesired effects (e.g., toxic effects) that might 
interfere with the desired effect.82,83 Another advantage is that an allosteric modulator is 
expected to work only at a time when an endogenous agonist is present at the orthosteric 
site.83 By this feature, the allosteric modulator effect would vary depending on the 
neuronal tone and the tissue state, which apparently differs from that of the orthosteric 
ligand that works in a continuous fashion irrespective to neuronal activity.83,84 A third 
advantage is the receptor subtype selectivity of allosteric ligands over classical 
orthosteric ligands and this is because the orthosteric sites of nAChRs are the most 
conserved region among this receptors subtype.20,83,84 
The main problem in the development of a drug discovery program toward 
noncompetitive inhibitors of nAChRs is the difficulty of identifying and quantifying 
allosteric modulators. Allosteric modulators are impossible to design a priori and 
serendipity is the common route of their identification.8,24,55,85,86 The current standard 
experimental approach for the determination of a noncompetitive inhibitor’s activity at 
nAChRs involves the use of concentration-dependent methods on whole cell currents87 or 
the nicotine-induced 86Rb+ cellular efflux model system.88 These approaches do not 
satisfy the requirement of efficient drug discovery practices as they are expensive, time-
consuming, and cannot be generalized to all nACh receptor subtypes.89 Even the use of 
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an efficient approach, such as displacement chromatographic techniques, assumes the 
existence of  known competitive displacers.90 To date, several allosteric sites on nAChRs 
have been identified, including three major sites that are present on all nAChR 
subtypes.89 Moreover, a wide variety of structurally diverse allosteric modulators of 
nAChRs have been reported over the last decade.8,24,55,85,86  
Allosteric ligand NAMs have gained great attention lately for their potential clinical 
applications. The primary effect of NAMs is to elevate the energy barrier between the 
receptor’s active and resting states.56 Medicinal chemistry efforts to identify novel 
allosteric ligands that selectively antagonize nACh receptor function are required. 
Kynurenic acid (KYNA; 17) (Figure 8) is a tryptophan metabolite, produced mainly 
in astrocytes, that has long been recognized as an NMDA receptor antagonist.91 It was not 
until recently that evidence showed KYNA at nanomolar concentrations, the normal level 
in the brain, to be the first endogenous negative allosteric modulator at α7 nAChRs, and 
that this can cause a marked reduction in striatal DA.92 These concentration limits are not 
enough to exert activity at the NMDA receptor.  Another NAM of α7 nAChRs reported 
by Yoshimura et al.,81 UCI-30002 (18; Figure 8), was discovered through a library 
screening of subtype A of the γ-aminobutyric acid (GABAA) receptor’s modulators for 
nAChRs. However, this compound lacks selectivity, and no evidence of its action as a 
NAM at α7 nAChRs was provided. Abdrakhmanova et al.93 reported in 2010 that 
1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-methylindeno[1,2,-b]pyrrole 
(HDMP; 19) (Figure 8) is a potent and selective NAM for α7 over α4β2 and α3β4 nACh 
receptors (IC50 = 0.07 µM). 
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meta-Chlorophenylguanidine (MD-354; 20) (Figure 8) was reported by our 
laboratory8,94 as the first subtype-selective small molecule to function as a NAM at α7 
nAChRs. MD-354 (20) does not bind at the orthosteric site of α4β2 (Ki > 10,000 nM) or 
α7 nACh receptors (Ki > 100,000 nM) but blocks the antinociceptive effect of the agonist 
Figure 8. The chemical structures of NAMs of α7 nAChRs: kynurenic acid (KYNA; 
17), and UCI-30002 (18), HDMP (19), and meta-chlorophenylguanidine (MD-354; 
20). 
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nicotine in the mouse tail-flick assay.8 Electrophysiological studies, using the whole-cell 
configuration of the patch-clamp technique to obtain functional data at stably transfected 
human embryonic kidney (HEK) 293 cells expressing rat α7 nAChRs, showed that MD-
354 (20) is a noncompetitive α7 nACh receptor antagonist (IC50 = 7.98 µM).8 The NAM 
activity of MD-354 (20) was confirmed through the elimination of possible competitive 
antagonism activity since competitive antagonists do not produce inhibition at currents 
evoked by an ACh-saturated concentration (Figure 9A). Also, the elimination of possible 
channel blocking activity was achieved by showing that MD-354 (20) produces a 
voltage-independent effect at various holding potentials (Figure 9B). However, MD-354 
(20) has been found to act as a partial agonist (in an in vivo model) at 5-HT3 receptors (Ki 
= 35 nM), in addition to its NAM activity at α7 nAChRs.8,95 The origin of the cross-
reactivity of many α7 nAChR and 5-HT3 receptor ligands is due to the high homology (~ 
30%) between the two receptor types, which is considered as the highest similarity within 
the LGIC superfamily.96  
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Figure 9. The inhibitory effects of MD-354 (20) at 10 µM at α7 nAChRs. (A) The 
inhibitory effects of MD-354 on α7 nAChRs at an EC50 concentration of ACh (i.e., 
280 µM) and at a saturated concentration of ACh (i.e., 1 mM). (B) The inhibitory 
effects at various holding potentials in the range from -100 to +30 mV. The upper part 
represents superimposed traces of ACh-induced currents in the absence and presence 
of 20. In the lower part, squares represent the maximal amplitude in the absence of 20 
plotted versus the corresponding holding potential, whereas circles represent the 
maximal amplitude in the presence of MD-354 (20) at a concentration around its IC50 
value plotted versus the corresponding holding potential.8,9 
(A) (B) 
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!Arylguanidine SAR for 5-HT3 receptor binding affinity showed that introduction of 
certain aryl substituents reduces the 5-HT3 receptor affinity of MD-354 (20) (Ki = 35 nM) 
(i.e., 21, 22, 23 (Figure 10); Ki = 2,340, 2,440, 1,600 nM; respectively) and that N-
methylation of the aniline nitrogen atom (i.e., 24; Figure 10) resulted in a significant 
reduction in affinity (Ki = 6,200 nM) as well.94,95 Although  these   structural alterations 
of MD-354 (20) are detrimental to 5-HT3 receptor binding, there is no reason to believe 
that the inhibitory activity (i.e., NAM action) at α7 nACh receptors will be affected. 
Based on this assumption, the inhibitory activity (i.e., IC50 values) at α7 nACh receptors 
of compounds 20 - 24, were obtained (Table 1).8,94,95 The resulting IC50 values showed 
that when the chloro group of MD-354 (20) is removed, potency is decreased (i.e., 21, 
IC50 = 34.84 µM). In the same manner, inhibitory potency is reduced when the chloro 
group of 20 is replaced with the more electron-withdrawing –CF3 group (i.e., 22; IC50 = 
18.46 µM). 
 
 
 
 
 
 
!
!! 32!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
 
HN
NH
NH2
Figure 10. Chemical structures representing different modifications of the MD-354 
(20) structure. 5-HT3 receptor affinity is provided [in brackets] as Ki values.94,95 
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Table 1. The IC50 values of MD-354 (20) and analogs for α7 nACh receptors, and their 
affinities at 5-HT3 serotonin receptors. 
 
 
 
 
 
 
 
 
* α7 nAChR IC50 value of 20 reported by Dukat et al.8  
** 5-HT3 receptor Ki values reported by Dukat et al.94,95 
 
Compound 23 (IC50 = 7.54 µM), where –OCH3 is an electron donating group at the 3-
position of the phenyl ring, showed a potency comparable to that of MD-354 (20) at α7 
nACh receptors; however, its low affinity at 5-HT3 receptors makes 23 a more selective 
α7 nACh receptor inhibitor than 20. A major increase in potency at α7 nACh receptors is 
shown by the N-methyl analog of MD-354 (i.e., 24; IC50 = 1.26 µM) (Figure 11).9 
Compound 24 exhibits a more than 1,000-fold shift in selectivity (5-HT3 receptor Ki = 
6,200 nM) and higher potency at α7 nACh receptors compared to 20 (5-HT3 receptor Ki = 
35 nM).9 Moreover, the NAM activity of 24 was confirmed through the elimination of 
possible competitive antagonism activity (Figure 12A) and the elimination of possible 
channel blocking activity (Figure 12B).9 Thus, it was demonstrated that the structural 
N
X
NH2
NH
R
Compound X R 
α7 nAChR 
IC50 ± SEM 
(µM) 
5-HT3 R 
Ki 
(nM)** 
20 H Cl 7.98*____ 35  
21 H H 34.84 ± 6.85 2,340  
22 H CF3 18.46 ± 0.42 2,440  
23 H OCH3 7.54 ± 0.74 1,600  
24 CH3 Cl 1.26 ± 0.26 6,200  
!
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requirements of the arylguanidines for 5-HT3 receptor binding, and actions as α7 nAChR 
NAMs, are not inextricably linked. 
!
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! Figure 11. Functional description of the N-methyl analog of MD-354 (i.e., 24) activity 
at α7 neuronal nAChRs.9 (A) A concentration–response relationship for different 
concentrations of 24 at α7 nAChRs where peak amplitude due to exposure to ACh 
(EC50)-evoked currents was normalized. The Hill equation was applied to the curve, 
and the symbols and bars represent the mean ± SEM. (B) The inhibitory effect of 24 at 
a concentration of 1 µM. The recorded results in (A) and (B) were performed at a 
holding potential of −80 mV. 
24 
(A) 
(B) 
 24 
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Figure 12. The inhibitory effects of 24 at 1 µM at α7 nAChRs.9 (A) The inhibitory 
effects of 24 on α7 nAChRs at an EC50 concentration of ACh (i.e., 280 µM) and at a 
saturated concentration of ACh (i.e., 1 mM). (B) The inhibitory effects at various 
holding potentials in the range from -100 to +60 mV. This represents superimposed 
traces of the ACh-induced currents in the absence and presence of 24. (C) The squares 
represent the maximal amplitude in the absence of 24 plotted versus the corresponding 
holding potential, whereas circles represent the maximal amplitude in the presence of 
24 at a concentration around its IC50 value plotted versus the corresponding holding 
potential. 
(A) (B) 
 24  24 
(C) 
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Figure 13. Effect ± SEM of 20, 21, 22, 23 and 24 at 10 µM concentration on 
acetylcholine (ACh) function at α3β4 nAChRs relative to ACh EC50 = 100 µM 
(normalized current = 1).9 
The activity of 20 - 24 at a fixed concentration of 10 µM at α3β4 nACh receptors was 
investigated to test the selectivity of these compounds among nAChR subtypes (Figure 
13).9 MD-354 (20) showed a lack of activity at 10 µM concentration on ACh at α3β4 
nAChRs relative to ACh at its EC50 concentration (EC50 = 100 µM) (Figure 14), whereas 
21 and 24 slightly attenuated the ACh (EC50 = 100 µM)-evoked currents. Compounds 22 
and 23 reduced the current of ACh to a different extent.9  
 
 
42 
 
currents at α3β4 nAChRs relative to ACh EC50 = 100 µM (Figure 20), whereas 31 and 40 
slightly attenuated the ACh (EC50 = 100 μM)-evoked currents. Compounds 45 and 46 reduced 
the current of ACh to a different extent.   
 
 
 
 
Figure 19. Mean effect of 21, 31, 40, 45 and 46 at 10 µM concentration on acetylcholine (ACh) 
function at α3β4 nAChRs relative to ACh EC50 = 100 µM (normalized current = 1). 
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MD-354 (20) neither displayed affinity (Ki > 10,000 nM) nor possessed functional 
activity at α4β2 nAChRs.9 The activity of 20, as well as 24, at α4β2 receptors was 
investigated as part of the selectivity test of these compounds among nAChR subtypes 
(Figure 15).9 Both compounds at concentrations comparable to the IC50 for α7 neuronal 
nACh receptors showed no activity on ACh (EC50 = 20 µM) at α4β2 nACh receptors. In 
addition, both compounds were examined for their agonist activity at α4β2 nACh 
receptors at their respective IC50 concentrations and failed to mimic ACh actions.9  
 
Figure 14. A) The effect of ACh (EC50 = 100 µM)-evoked current at α3β4 nAChRs. B) 
The effect of MD-354 (20) at 10 µM concentration on ACh (EC50 = 100 µM)-induced 
current at α3β4 nAChRs.9 Holding potential for these recording was - 80 mV. 
(A) (B) 
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 24        
 24        
 24        
(C) (D) 
Figure 15. Effect of MD-354 (20) and 24 on α4β2 nAChRs.9 (A) Effect of ACh at 
EC50 = 20 µM and saturated concentrations = 1 mM. (B) Effect of MD-354 (20) on 
ACh (EC50 = 20 µM)-evoked current and by itself at α4β2 nAChRs. (C) Effect of ACh 
(EC50 = 20 µM) alone and effect of ACh at EC50 = 20 µM accompanied by 10 µM of 
24. (D) Effect of 24 at 1 µM on ACh (EC50 = 20 µM)-evoked current and by itself at 
α4β2 nAChRs. Holding potential for these recording was - 80 mV. 
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Further investigations for the required structural features of these small-molecule 
were applied to determine and optimize their NAM activity at α7 neuronal nAChRs.9 
Considering the functional data from MD-354 (20) and its N-methyl analog 24, since the 
N-methyl group is known to be detrimental to 5-HT3 receptor binding, a new series of 
compounds was synthesized.9 The chloro group at the 3-position of N-(3-chlorophenyl)-
N-methylguanidine (24) was replaced with a number of substituents considering the 
electronic, the lipophilic, and the steric nature of the new substituent (Table 2).9 In 
addition, the activity of any new modification at α7 nACh receptors was compared to that 
determined for the same modification in the MD-354 series to test if parallel structural 
modification would result in parallel change in activity, which might suggest whether or 
not the two series bind at the same manner (Table 2).9  
The functional data on two compounds of each series (i.e., 20 and 21 of MD-354 
series, and 24 and 25 of the new N-methyl series) revealed the inhibitory activity of these 
compounds at α7 nACh receptors.9 Removal of the chloro group from 20 (i.e., 21) 
resulted in around a four-fold reduction in the current (Table 1). In contrast, removing the 
chloro group from 24 (i.e., 25; IC50 = 30.81 ± 2.13 µM)9 results in around a thirty-fold 
reduction of its effect. However, the number of compounds tested here might not be 
sufficient to confirm that the N-methyl series binds in the same manner with α7 nAChRs 
as MD-354 series.9 The possibilities that the N-methyl series might bind to a different 
allosteric site than that of the MD-354 series, or that the N-methyl series could bind to the 
same allosteric site as that of the MD-354 series, remain to be considered.  
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a π and σm aromatic R substituent constants reported by Hansch et al.97!
 
 
 
 
Compound R πa σm a Compound 
20 Cl 0.71 0.37 24 
21 H 0.00 0.00 25 
31 Br 0.86 0.39 26 
32 F 0.14 0.34 27 
33 I 1.12 0.35 28 
34 CH3 0.56 -0.07 29 
23 OCH3 -0.02 0.12 30 
Table 2. Structural representation and substituent constants of the N-methyl series and 
the MD-354 series of arylguanidines. 
MD-354  
Series 
N-methyl 
Series 
N
X
NH
NH2
H3CHN
X
NH
NH2
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F. Clinical Implications of α7 nAChR Ligands 
 
The discovery of small molecules that influence α7 nAChR activity would be of great 
importance. As research tools, they would enhance our understanding of the roles that 
nAChRs play in physiological and pathological states. Furthermore, they hold clinical 
promise as therapeutic agents for disorders associated with nAChRs.  
 
1. Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with a slow and 
progressive loss of memory and cognition.98 The neuropathology of AD is characterized 
by the presence of two types of abnormal deposits, cortical senile (amyloid) plaques (SP) 
and neurofibrillary tangles (NFT) that, consequently, cause extensive neuronal loss.98 
Evidence showed that α7 nAChRs mediate the pathology that leads to the formation of 
these AD hallmarks.98,99 
Controversially, both agonists and antagonists of α7 nAChRs can offer benefits not 
only for symptomatic therapy, but also for decreasing the progression of AD.100,101 
Apparent explanation of the desired effects of agonists might be related to the fact that α7 
nAChRs desensitize (i.e., reducing cholinergic transmission) rapidly after exposure to 
agonists such as nicotine.100,102 Conversely, antagonists directly attenuate nAChR-
mediated transmission.100-102 Another explanation suggests that α7 nAChR ligands 
prevent the toxic effect of the high-affinity binding of β-amyloid peptide 1-42 (Aβ1-42) to 
the α7nAChRs and, consequently, prevent Aβ1-42 cellular internalization.101 
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Current clinically approved drugs to treat mild-to-moderate AD cause inhibition of 
acetylcholinesterase, the enzyme responsible for the hydrolysis of the neurotransmitter 
ACh.103 These drugs include galantamine (13; Figure 7), donepezil, and rivastigmine 
(structures not shown). These drugs, when co-administered with other therapies, show a 
reduction in cognitive impairment in small samples of patients with schizophrenia.63,103 
Although these results were derived from open, uncontrolled studies, only galantamine 
showed positive outcomes when applied as an add-on therapy for a small randomized 
sample in a double-blind trial, and no positive results were detected with donepezil or 
rivastigmine.63 
 
2. Marijuana Addiction 
 
The nucleus accumbens (NAc) and ventral tegmental area (VTA) are two major 
compartments of the mesolimbic dopamine system that are responsible for addictive 
properties of abused drugs (Figure 1). Both the NAc shell and the VTA express α7 
nAChRs.104 The activation of these receptors causes the release of glutamate and the 
activation of ionotropic glutamate receptors, which, consequently, stimulates dopamine 
release at dopaminergic terminals.105 There is evidence that animals treated with Δ9-
tetrahydrocannabinol (THC), the primary constituent responsible for marijuana abuse and 
dependence, experience elevation in mesolimbic dopamine transmission, whereas a 
reduction in mesolimbic dopamine transmission is observed during drug withdrawal.106 
Furthermore, methyllycaconitine (9; Figure 5), a relatively selective α7 nAChR 
antagonist, blocks the behavioral rewarding properties and neurochemical actions of 
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THC.7 This implies a possible role of modulation by α7 nAChR activity and indicates the 
pharmacological potential of α7 nAChR antagonists for treating marijuana dependence. 
Inhibition of presynaptic α7 nAChRs was recently investigated as a useful approach 
to treat the withdrawal symptoms of marijuana.106 Kynurenic acid (KYNA; 17) (Figure 8) 
is an endogenous noncompetitive antagonist at α7 nAChRs.91 Studies showed that KYNA 
(17) was capable of lowering extracellular glutamate and, consequently, reduced the 
release of dopamine in the striatum and prefrontal cortex.92,106 Therefore, targeting 
presynaptic α7 nAChRs with a potent antagonist might provide a valuable tool for the 
treatment of drug dependence and other dopamine-related disorders.  
 
 
3. Depression 
 
Ketamine (Ket; 35) (Figure 16) is a chiral drug known to act as an N-methyl-D-
aspartate (NMDA) receptor antagonist, but it also acts at numerous other targets 
including nAChRs.107 Ket (35) is known clinically for its anesthetic properties; however, 
it is associated with several other advantageous properties such as potentiation of the 
opioid analgesic effect, an anti-inflammatory effect, anti-tumor effect and antidepressant 
effect.107,108 In an effort to study the pharmacological activity of Ket (35) and its 
metabolite norketamine (norKet), Moaddel et al.109 investigated their antidepressant 
properties using sub-anesthetic dosing of Ket in treatment-resistant patients. Data 
indicated that there are strong links between the antidepressant effect and the plasma 
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levels of diastereomeric hydroxynorketamine (HNK) and some of the HNK metabolites 
that are normally found in circulating blood obtained from patients.109,110 This study also 
showed that only one particular isomer (i.e., (2S,6S)-HNK; 36) (Figure 16), out of the 
other major metabolites, was the most potent in in vitro studies.109,110 The 
pharmacological activity of this metabolite was tested, later, at NMDA receptors, α7 
nAChRs, and α3β4 nAChRs and results showed that (2S,6S)-HNK is a potent and 
selective NAM at α7 nAChRs with no detection of anesthetic activity in rat.109,110 
 
!
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Activity at presynaptic α7 nAChRs results in a potential consequence on the activity 
of the enzyme serine racemase (SR).111 SR is a Ca2+-dependent enzyme that works to 
increase the intracellular level of D-serine (D-Ser). Endogenous D-Ser is a known co-
agonist of NMDA receptors, and a long-term potentiator that is associated with NMDA-
Figure 16. The chemical structures of NAMs of α7 nAChRs: ketamine (Ket; 35), and 
(2S,6S)-HNK (36). 
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induced neurotoxicity.111,112 The inhibition of α7 nAChRs lowers intracellular Ca2+ levels 
that, in turn, decreases SR activity and, consequently, endogenous D-Ser levels. Thus, 
potent and selective antagonists of α7 nAChRs might represent promising antidepressant 
agents through the indirect modulation of NMDA receptor activity.109,110,112 
 
4. Lung Cancer 
 
During the period between 1989 and 1994, several publications described the 
presence and the potential importance of nicotinic receptors in lung cancer cells.113-116 In 
addition, the presence of ACh and all the required components for its synthesis and 
activity such as CAT and nAChRs in human airway epithelial cells widened the 
possibility of different pathological roles in the periphery.113-116 Exposure to nicotine 
through tobacco smoke or cigarette substitutes can initiate the proliferation of a variety of 
small-cell lung carcinoma cell lines and endothelial cells.117,118 This effect is also seen in 
structurally-related carcinogens such as 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone 
(NNK) and N'-nitrosonornicotine (NNN) which also can reach non-neuronal tissues and 
increase the production of growth factors (e.g., TGF-α, and VEGF). These factors 
eventually lead to protein upregulation and activation of the Raf/MEK/ERK pathway that 
is associated with tumor development and progression.117,118  
Numerous laboratories have reported the observed transformations of pharmacologic 
doses of tobacco and other carcinogenic nitrosamines on different cell lines.118 In an in 
vitro study analyzing the level of gene expression of nAChR subtypes in smokers’ and 
nonsmokers’ non-small-cell lung cancer (NSCLC) tissues after 72 hours exposure to 
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nicotine (0.1 µM) indicated a significantly reversible upregulation of α1, α5, and α7 
subunits in bronchial epithelial cells.119 Other studies reported a major role for α7 
nAChRs over other nicotinic receptor subtypes in mediating nicotine’s proliferative 
properties in lung tumor cells.120-122 Although there are several studies investigating the 
possible mechanisms and the contributing factors for carcinogenesis in different types of 
lung tumors, the involvement of nicotinic receptors, in particular α7 nAChRs, represents 
a separate and unique therapeutic approach that might provide an unprecedented 
opportunity for progress.118 
 
G. Molecular Characteristics of Human α7 nAChRs  
 
The cDNA of the human α7 receptor subunit encodes a polypeptide of 502 amino 
acid residues.98,123 The human α7 protein subunit is about 56 kDa and is composed of 222 
amino acids forming the ECD, 87 amino acids forming the TMD, and 152 amino acids 
forming the ICD.123 Important regions on the primary sequence of α7 nAChR subunit 
were identified, including the orthosteric binding site (i.e., loops A, B, C, D, E, and F) 
(Figure 17).123 The essential amino acids involved in orthosteric ligand recognition are 
Trp171, Tyr115, Tyr217, and the adjacent two cysteine residues (Cys212 and Cys213) 
forming the disulfide bond at the C loop.123 There are also the well-known two cysteine 
residues (i.e., Cys150 and Cys164) that form the disulfide bond characterizing the Cys-
loop family of receptors (Figure 17).123 
The level of sequence identity between human α7 subunits and the different subunit 
classes of the nACh receptors is approximately 41%.124 For interspecies comparison, the 
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human α7 subunit is highly conserved, exhibiting 94% and 92% amino acid sequence 
identity to rat and chicken receptors (Figure 17), respectively.123 This high sequence 
identity implies that there are very few sequence differences among human, chicken, and 
rat α7 receptors to account for pharmacological differences between species. 
The transmembrane sequences are identical in all three species.123 The M2 sequence 
is the transmembrane portion responsible for lining the ion channel and, as expected, 
shows an identical amino acid sequence to those of homomers of α7 from chickens and 
rats.123 The most sequence diversity is in the large intracellular loop connecting M3 and 
M4, as is typical for interspecies sequence variation of nAChR subunits.123 
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Figure 17. Multiple sequence alignment of three amino acid sequences (i.e., human, 
rat, and chicken α7 nAChR monomers) showing a high degree of identity. Amino acid 
residues forming the orthosteric site are: red, loop A; blue, loop B; yellow, loop C (for 
the principal subunit ribbon); and green, loop D; orange, loop E; purple, loop F (for 
the complementary subunit ribbon). 
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H. Previously Reported Molecular Models of Human α7 nAChRs 
 
The significance of molecular modeling, as an important computational tool in drug 
design, is widely appreciated.125 The level of structural information to be gained from 
these models might provide tremendous insight for interpreting pharmacological data. 
Among several interesting biological targets, molecular modeling studies on α7 nAChRs 
gained much attention and were reported in a number of scientific papers.74,80,126-129 The 
motivation for these studies is to explore and learn more about the structural basis of the 
molecular effect on α7 nAChRs through homology modeling and ligand docking. In 
addition, molecular information was also obtained from the publication of crystal 
structures of similar protein targets that share acceptable sequence identity with α7 
nAChRs.129 
In 2006, two models of α7 nAChRs were introduced.  The first one was by Iorga et 
al.126 where they docked three allosteric modulators seeking the identification of their 
potential binding site(s) at the ECD (see Table 3). The second model was by Cheng et 
al.127 where they studied the gating motion of the receptor. The differences between the 
two models was the crystal structure template used for homology modeling.126,127 
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Table 3. Summary of previously reported models of α7 nAChRs for identifying possible 
allosteric binding sites. 
  
Iorga et al.126 Brannigan et al.129 
ECD 
Template AChBP  
(1UV6)  
Cavity Search 
Software 
Alpha spheres 
(MOE)  
Blind Docking 
Software AutoDock  
TM 
Template 
 
Torpedo m. (2BG9) 
Cavity Search 
Software  Molecular dynamic 
simulation 
“flooding” Blind Docking 
Software  
 
 
Young et al.74 constructed a homology model of human α7 nAChRs in 2008, based 
on the 4 Å crystal structure of the Torpedo nAChR. Their aim was to predict the binding 
modes of two PAMs (i.e., PNU-120596 and LY-2087101) at the intrasubunit cavity. The 
following year, Luttmann et al.128 presented a model for the extracellular portion of the 
human α7 nAChR. The model was used to identify possible binding sites for 
allosterically-potentiating ligands (APLs) by searching for cavities and blind-docking 
experiments with several APLs. Collins et al.80 also used a homology model of the human 
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α7 nAChR TMD to investigate the binding modes of ivermectin in 2010. The binding site 
was proposed to be in the intrasubunit cavity located between the four transmembrane α-
helices.80  
Brannigan et al.129 investigated the binding sites of the general anesthetic isoflurane 
in the TMD of nAChRs. The nAChR from Torpedo was subjected to computation-based 
“flooding” (i.e., simulating a high concentration of anesthetic in the surroundings) of the 
receptor and was allowed to partition in the system over the course of an MD simulation 
trajectory (Table 3). Their aim was to reduce potential errors that might arise from 
homology models.  
All the published models mentioned above investigated different aspects of structural 
information. Only two models, out of them, were generated to explore the possible 
binding site of galantamine (13) and isoflurane in the α7 nAChR ECD and TMD, 
respectively, and these are shown in Table 3.126,129  
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III. Specific Aims 
 
 
 
Within the nAChR family as attractive therapeutic targets for drug discovery, 
considerable effort has been aimed toward the identification and development of drugs 
that target α7 nAChRs. The binding sites of the endogenous neurotransmitter ACh (i.e., 
orthosteric binding sites) have been the major concern of many drug discovery efforts. 
The main objective of research projects targeting orthosteric sites is to identify drugs that 
bind to these sites of α7 nAChRs and produce better activation or inhibition of the 
endogenous ligand ACh. Nevertheless, one conceivable problem that attenuates the value 
of this approach is the difficulty of identifing drugs with adequate subtype-selectivity due 
to the high level of sequence homology within the orthosteric binding sites of different 
nAChR subtypes.25 The lack of subtype-selective drugs for α7 nAChRs can result in 
several undesirable side effects and, thus, limits their clinical use as therapeutic agents. 
For example, activation of α4β2 nAChRs can be accompanied by nausea and vomiting, 
whereas activation of α3β4 nAChRs at autonomic ganglia and in the CNS is associated 
with constipation and weight loss, respectively.130,131 Accordingly, projecting efforts 
toward the regulatory binding sites (i.e., the allosteric binding sites) that are at distinct 
locations from the highly conserved ACh-binding site (i.e., the orthosteric site) has 
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gained increasing attention as a promising approach to developing α7 nAChR drugs. 
Allosteric binding sites are topologically distinct from the orthosteric binding site and can 
represent promising targets for the development of subtype-selective α7 nAChR 
drugs.20,25  
This dissertation focuses on the discovery and development of small-molecule 
arylguanidines that modulate α7 nAChR function with improved subtype-selectivity that 
might be achieved through the allosteric approach. Identifying the required structural 
features of these small molecules will allow for optimizing their NAM activity at α7 
neuronal nAChRs. The two previously synthesized series of compounds identified by our 
laboratory, based on MD-354 (20) and its N-methyl analog 24 (Table 2),9 were used as a 
starting point to determine the effect of modifications on NAM activity of both series. 
Furthermore, the effect of these parallel structural modifications might suggest whether 
or not the two series bind at the same allosteric site and, if so, if they bind in a similar 
manner (Table 2).9  
The present study was aimed toward identifying novel chemical classes of agents that 
bind to allosteric binding sites and antagonize α7 nAChR function (i.e., negative 
allosteric modulators; NAMs). The primary goals of this research are as follows:  
 
A. QSAR 
The identification of the physicochemical properties essential for α7 nAChR NAM 
activity is a key approach in current drug discovery and development methods. This step 
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can be addressed through quantitative structure-activity relationship (QSAR) studies on 
closely related analogs possessing the same core structure. QSAR studies are based on 
the Hansch assumption of activity–modification of a parent compound by a binding site 
that recognizes chemical substituents by specified lipophilic (π), electronic (σ), and other 
properties.132  
Previous molecular modeling studies at the ECD of α7 nAChRs9 were analyzed using 
SYBYL 8.1. Docking of both 20 and 24, performed by the GOLD Suite 5.0 program, 
showed plausible binding modes in an allosteric site (characterized by a Thr221) and 
revealed two main clusters (Figure 18).9 The rotamers of 20 appeared to utilize the same 
binding mode (N1 and N2 form ionic hydrogen bonds with Asp219; hydrophobic 
interactions exist between the phenyl ring and Thr221) with alternate locations of the 
chloro group (possible hydrophobic interaction with the aliphatic chain of Lys204). In 
contrast, N2 and N3 of 24 form ionic hydrogen bonds with Asp219 as the major difference 
detected at this allosteric site. N3 shows further a hydrogen bond interaction with Thr221. 
The introduction of an N1-methyl group to MD-354 (i.e., 24) appears as the key 
difference in activity since the methyl group on N1 precludes ionic hydrogen bonding 
with Asp219 (Figure 18).9   
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The two possible binding modes add to the necessity of investigating the structural 
requirements for the binding of arylguanidines at α7 nAChRs. The purpose of this study 
is to analyze the structural requirements of these compounds that act as NAMs using a 
Hansch analysis.132 Analogs of the MD-354 series and the N-methyl series with parallel 
structural modifications will be synthesized and investigated. The physicochemical 
properties associated with other halogens (i.e., -F, -Br, and -I) in place of the chloro 
group will allow for testing mainly the effect of substituent size variation over a relatively 
fixed  electron-withdrawing   nature  (Table 4).  Replacement  of  the  chloro group with a 
-OCH3 or -CH3 group as electron donating groups will explore the effect of such 
modifications on activity (Table 4). For the -CF3 group, there is a greater electron 
HN NH2
N
Cl
D H H
H
D
Cl
N
CH3
HN
N
1 
2 
3 3 
2 
1 
Figure 18. Binding modes of 20 and 24 at the ECD allosteric site (characterized by a 
Thr221) of α7 nAChRs as suggested by preliminary molecular modeling studies.9 D = 
Asp219. 
MD-354 (20)  
 
24 
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withdrawing nature than -Cl and other halogens. However, the -CF3 group has a lower 
relative electron affinity (EA) than -Cl, a property that provided an explanation for the 
lower binding   affinity of -CF3-substituted arylguanidines than -Cl-substituted 
arylguanidines to 5-HT3 receptors.133 
 
 
Table 4. Structural representation of different modifications at the 3-position of the MD-
354 (i.e., 20) series and the N-methyl (i.e., 24) series of arylguanidines. 
 
 
 
 
 
 
 
 
 
 
Compound X Compound 
   
21 H 25 
20 Cl 24 
31 Br 26 
32 F 27 
33 I 28 
22 CF3 37  
34 CH3 29 
23 
 
OCH3 30 
HN
X
NH
NH2 N
X
NH
NH2
H3C
MD-354 (20) 
Series 
N-Methyl (24) 
Series 
!! 57!
Hansch-type QSAR studies will be conducted using several physicochemical 
properties such as π (hydrophobic constant), σm (Hammett electronic constant), L 
(Verloop length), B1 (Verloop minimum width), B5 (Verloop maximum width), MR 
(Molar Refraction), and solvent accessible volume (Vol) (Table 5). This study also 
involved application of a widely accepted concept proposed by Portoghese134 in his study 
on analgesics, which suggests that “If identically substituted compounds in two different 
series are interacting with receptors in a similar manner, then the quantitative 
contribution of various substituents to the … effect should produce, under steady-state 
conditions, proportionate variations of activity in both series”. 
Table 5. Description of various physicochemical parameters. 
Parameter Description 
π Hydrophobic constant132 
σm Hammett electronic constant132 
L Verloop length of the substituent159 
B1 Verloop minimum width of the substituent159 
B5 Verloop maximum width of the substituent159 
MR Molar refraction160 
Vol Solvent accessibility volumea 
NVE Number of valence electron (Verma et al.) 
CMR Complete molar refractionb 
MV Molar volumec 
Pc Parachor based on surface tension and MVc 
Polarizability Polarizability of the compoundc 
a Calculated by Chimera 
b Calculated by ChemDraw 
c Calculated by ChemSketch 
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Hypothesis 1 is that 3-position substituents control the potency of arylguanidines at α7 
nAChRs, and that this is related to the physicochemical attributes of these substituents. 
This can be evaluated by conducting QSAR studies. 
Hypothesis 2 is that arylguanidines and their N-methyl counterparts bind in a dissimilar 
manner at α7 nAChRs (as shown in Figure 18). This can be addressed by examining two 
related series of compounds to determine if parallel structural changes result in parallel or 
non-parallel shifts in NAM potency in accordance with the Portoghese Hypothesis. 
 
B. Topliss Tree 
 
The Topliss Tree approach is a non-mathematical guide for the use of the Hansch 
principle.135 The Topliss Tree, usually with the guidance of the Craig Plot,136 allows for 
an efficient optimization of the potency of a lead compound with minimal number of 
compounds needed to be synthesized. The Topliss operational scheme for the aliphatic 
side chain (Figure 19) will be used to optimize pharmacological activities associated with 
the alkyl group at the anilinic nitrogen (i.e., N1) of the arylguanidines at α7 nAChRs. 
Furthermore, we hope to develop a better understanding of how small-molecule NAMs 
interact at α7 nAChRs. 
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Accordingly, replacement of the N1 methyl group in the N-methyl guanidine series 
(i.e., 24, 25) with an isopropyl (i-Pr) group (i.e., 38, 39; Table 6) should increase its π 
effect.135 The isopropyl group not only provides more lipophilic character, but also adds 
more steric bulk than the methyl group. By examining this structural feature, we can 
determine how much bulk can be tolerated by α7 nAChRs for optimal NAM activity. A 
total of four pairs of compounds will be examined through which the necessity of the 
chloro group will be also investigated with deschloro compounds (Table 6).  
Figure 19. Schematic representation of the Topliss decision-tree for aliphatic side 
chain substituents (M, more potent; E, equipotent; L, less potent). Adopted from 
Topliss.135 
CH3 
i-Pr 
H, CH2OCH3, 
CH2SO2CH3 
C2H5 
CHCl2, CF3… 
End 
Cyclopentyl 
Cyclobutyl.. 
Cyclohexyl.. 
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Table 6. Structural representation of proposed compounds with different modifications at 
the N1 and 3-position. 
 
 
 
 
 
 
Hypothesis 3 is that application of the Topliss scheme should allow optimization of the 
N1 substituent of arylguanidines as α7 nAChR NAMs, if the size and/or lipophilic nature 
of the substituent contributes to activity. 
 
 
 
 
 
Compound R X 
21 H H 
20 H Cl 
25 CH3 H 
24 CH3 Cl 
38 CH(CH3)2 H 
39 CH(CH3)2 Cl 
   
NR NH2
NH
X
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C. Role of the Guanidine Nitrogen Atoms 
 
To gain an understanding of the role of the guanidine nitrogen atoms in the inhibitory 
effects of arylguanidines on α7 nACh receptor function, a series of compounds will be 
tested (Figure 20). The compounds in this series retain the 3-chlorophenyl moiety, 
whereas the differences appear at the guanidine part. With the first compound in this 
series, we will test the effect of substitution at a guanidine terminal nitrogen atom (i.e., 
40; Figure 20) on NAM activity. In the remaining compounds of this series, the guanidine 
is replaced with modified forms of substructures representing the guanidines missing one 
or two nitrogen atoms (i.e., 41, 42, and 43). Our purpose here is to understand the 
minimum structural requirement of the guanidine moiety needed for the NAM activity at 
α7 nAChRs. In addition, this can provide further insight on the specific molecular 
interactions of arylguanidines NAMs at α7 nAChRs. 
Hypothesis 4 is that not all of the three guanidine nitrogen atoms (or NH functions) are 
required for α7 nAChR NAM actions. This can be examined by investigating compounds 
where the NH moiety is replaced by an N-methyl group (i.e., 40), where the NH moiety is 
replaced by a methylene group (i.e., 41), or eliminated altogether (i.e., 42). Compound 43 
represents an arylguanidine where basic properties have been eliminated (i.e., 43 is an 
amide). 
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Figure 20. The chemical structures of modified forms of arylguanidines. 
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D. Molecular Modeling 
 
1. Homology Modeling and Docking Studies 
 
The primary goal of our molecular modeling studies is to construct and validate a 
homology model of the active α7 nAChR. The constructed model will be used to identify 
the putative allosteric binding site(s) and to determine the interaction mode(s) of the 
studied compounds with α7 nAChRs. Since the α7 nAChR is a homomeric structure, the 
molecular modeling of only two attached subunits (i.e., a dimer) is justified, and should 
be sufficient to mimic the essential ligand binding domain. The construction will undergo 
a number of steps and different software will be employed. Aligning the amino acid 
sequence of the targeted portion of the protein with the matching portion of the selected 
template amino-acid sequence will be performed using ClustalX 2.0.137 The generation of 
multiple models lacking validation will be constructed using Modeller 9.12. Different 
docking programs (e.g., GOLD Suite 5.2 and AutoDock 4.2), as well as accurate residue 
orientation methods, should allow for model validation by comparing the results with 
previously published biochemical or crystallographic data. Therefore, the blind docking 
feature of AutoDock 4.2 using Gal (13) and the Connolly surface feature of SYBYL-X 
2.1 will be used to explore the possible interaction site(s) at the ECD and the TMD of α7 
nAChRs. GOLD Suite 5.2 will be used for model validation through the docking of α7 
nAChR agonists (i.e., ACh, nicotine (1), EPI (3)) and the antagonist MLA (9) and 
comparing the results with reported crystal structures (PDB ID: 2XZ5, 1UW6, 2BYQ, 
and 2BYR, respectively).138-140 Further validation will be performed by docking of α7 
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nACh receptor modulators (i.e., Gal (13) for ECD, PNU-120596 (15) and ivermectin (16) 
for TMD). Prior to docking of the molecules, we will select the favorable low-energy 
conformations that were previously reported as a result of a systematic search 
investigation.9 The validated ECD and TMD models of α7 nAChRs will then be used for 
the new docking studies after specifying the targeted allosteric cavity. The resulting 
complexes of compounds with the candidate ECD and TMD models of α7 nAChRs will 
be rescored with the HINT (Hydropathic INTeractions) program,141 an empirical scoring 
function based on the experimental free energy information derived from log Po/w (the 
solvent partition coefficient for 1-octanol/water). The obtained candidate complexes of 
docked compounds at the ECD models of α7 nAChRs will provide beneficial information 
that will help in the prediction of required structural modifications to the current series. 
 
2. Crystal Structures of Guanidines 
 
For any bimolecular interaction in biological systems, the existence of specific 
attractive forces controls their molecular recognition.125 Sufficient knowledge about the 
nature of these specific interactions and their geometries, usually through their crystal 
structures, can offer valuable insight for medicinal chemists seeking innovative ways for 
drug development.125 When a lead compound has been identified, the optimization 
process of its specific attractive interactions becomes a promising approach.    
Through reviewing the literature for molecular interactions and analyzing the specific 
interactions for a molecule of interest, we hope to reach a deeper understanding of how 
guanidines, as a key structural moiety in our series of compounds, might interact with α7 
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nAChRs. The approach of optimizing geometry of binding of guanidine compounds with 
their protein targets was used, previously, in a number of literature studies for the 
development of new guanidine analogs.142,143 As a valued resource for the nature of 
molecular interactions, we investigated the PDB database for molecular interactions of 
guanidine-containing ligands. We found eight available crystal structures (i.e., PDB IDs: 
1S6F, 1S5S, 2VNT, 1ZMJ, 1ZML, 1ZMN, 3PO1, and 3HPT) including guanidine-
containing ligands interacting with different types of serine protease enzymes.144-148 
Besides that, identifying these key interactions can be used as references for predicting 
the binding mode of our arylguanidine compounds. 
Overall, our eventual aim is to rationally design α7 nAChR NAMs with desired 
physicochemical and biological properties using multiple medicinal chemistry 
approaches.  
Hypothesis 5 is that the continual flow of data obtained from different parts in this 
project (e.g., biological data and molecular modeling studies) can be integrated using 
medicinal chemistry approaches to identify and optimize arylguanidines as NAMs of α7 
nAChRs.  
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Previous knowledge of the reported allosteric binding sites on α7 nAChRs as well as 
α7 nAChR NAMs can also be utilized to provide a rationale for designing novel α7 
nAChR NAMs.   
 
The specific aims of the current project are:   
a) Determination of the similarity or dissimilarity of the binding modes of the MD-354 
series and the N-methyl series of arylguanidines at α7 nAChRs. 
b) Identification of what structural features of the 3-position in the arylguanidine 
compounds contribute to the activity profile of α7 nAChR NAMs. 
c) Optimization of the alkyl substituent at the anilinic nitrogen atom of arylguanidine 
NAMs. 
d) Investigation of the role of the nitrogen atoms in the guanidine moiety of 
arylguanidine compounds for the inhibition profile at α7 nAChRs. 
e) Identification of the potential allosteric binding site and the mode of interactions of 
arylguanidine NAMs at α7 nAChRs. 
f) Identification of a pharmacophore for small-molecule arylguanidine inhibitors for α7 
nACh receptor action.  
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IV. Results and Discussion 
 
 
 
A. Synthesis 
 
The nitrate salt of m-chlorophenylguanidine (MD-354; 20), the hydrochloride salt of 
phenylguanidine (PG; 21), the nitrate salt of 3-trifluoromethylphenylguanidine (22), the 
hemisulfate salt of 3-methoxyphenylguanidine (23) and the hydrochloride salt of 3-
methylphenylguanidine (34) were available from previous studies.94,95 The syntheses of 
the hydrochloride salt of N-(3-chlorophenyl)-N-methylguanidine (24), the hydrochloride 
salt of N-methyl-N-phenylguanidine (25), the hydrochloride salt of N-(3-bromophenyl)-
N-methylguanidine (26), the hydrochloride salt of N-(3-fluorophenyl)-N-methylguanidine 
(27), the hydrochloride salt of N-(3-iodophenyl)-N-methylguanidine (28), the nitrate salt 
of N-(3-methylphenyl)-N-methylguanidine (29), and the hydrochloride salt of N-(3-
methoxyphenyl)-N-methylguanidine (30) were reported in our previous work.9 
N-Methyl-3-trifluoromethylaniline nitrate (37) was prepared in three steps according 
to a previously published procedure described for similar compounds (Scheme 1).149-151 A 
first unsuccessful attempt was made to synthesize the ethyl N-[3-(trifluoromethyl)phenyl] 
carbamate (46). In this attempt, ethyl chloroformate was added to a solution of 3-
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trifluoromethylaniline (44) and triethylamine in Et2O and the reaction mixture was heated 
at reflux for 1 h resulting in a major product of urea derivative 45 (i.e., dimeric product). 
An alternative condition to obtain the desired intermediate carbamate 46 was used; ethyl 
chloroformate was added in a dropwise-manner to a solution of 3-trifluoromethylaniline 
(44) and sodium hydride to yield the desired carbamate in 88% yield. The carbamate 46 
was then reduced to N-methyl-3-trifluoromethylaniline using LiAlH4 in THF and the HCl 
salt 47 was prepared. An ethanolic solution of 47 was heated at reflux with cyanamide to 
give 37. The structure of the compound was confirmed by IR, 1H NMR, and elemental 
analysis for C, H, N. 
 
Scheme 1.a 
 
 
 
 
 
 
aReagents and conditions: a. ethyl chloroformate, Et3N, Et2O, reflux; b. ethyl 
chloroformate, NaH, THF, reflux; c. LiAlH4, THF, reflux; d. HCl/Et2O; e. NH2CN, 
absolute EtOH, reflux; f. NH4NO3, H2O. 
44 
46 47 37 
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Scheme 2 describes the synthesis of N-isopropyl-N-phenylguanidine nitrate (38). The 
synthesis consisted of a one-step reaction according to a literature procedure for a similar 
compound.152 Cyanamide was reacted with N-isopropylaniline hydrochloride (48) in 
EtOH. The hydrochloride salt of N-(3-methylphenyl)-N-methylguanidine was 
hygroscopic and, because of that, was converted to the nitrate salt using ammonium 
nitrate. The structure of N-isopropyl-N-phenylguanidine nitrate (38) was confirmed by 
IR, 1H NMR, and elemental analysis for C, H, N. 
 
Scheme 2.a 
 
 
 
 
 
 
aReagents and conditions: a. i) NH2CN (50% aqueous), EtOH, reflux; ii) NH4NO3, H2O. 
 
N-(3-Chlorophenyl)-N-isopropylguanidine hydrochloride (39) was prepared as 
described in Scheme 3. This was an unknown compound at the time of synthesis, but was 
prepared according to a literature procedure for a similar compound.151,153 3-
Chloroaniline (49) was treated with 2-bromopropane (50) in the presence of an aqueous 
solution of NaOH, allowing for a nucleophilic substitution reaction to yield the 3-chloro-
NH
CH3
H3C
a N NH2
NH
H3C
CH3
HCl 
HNO3 
48 38 
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N-isopropylaniline (51). The final step was performed by heating an ethanolic solution of 
the hydrochloride salt of 51 at reflux with cyanamide to give 39. The desired compound 
was confirmed by IR spectrometry, 1H NMR spectrometry, and elemental analysis for C, 
H, N. 
 
Scheme 3.a! 
 
 
 
 
aReagents and conditions: a. NaOH (15% aqueous), ZnCl2 (saturated aqueous), 150 °C; 
b. HCl/Et2O; c. NH2CN, EtOH, reflux. 
 
Based on the initial biological results obtained for compounds 38 and 39, compounds 
52 and 53 were synthesized (see discussion below). N-Ethyl-N-phenylguanidine 
hydrochloride (52) was synthesized according to a literature procedure in a one-step 
reaction as described in Scheme 4.154 The N-ethylaniline hydrochloride (54) was allowed 
to react with a cyanamide in 1-pentanol. The desired product obtained was confirmed by 
IR, 1H NMR, and melting point. 
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H3C CH3
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N NH2
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H3C
CH3
Cl
HCl a,b c 
49 50 39 51 
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Scheme 4.a 
 
 
 
 
aReagents and conditions: a. NH2CN, 1-pentanol, reflux. 
 
Scheme 5 summarizes the synthesis of N-(3-chlorophenyl)-N-ethylguanidine 
hydrochloride (53). This was an unknown compound at the time of synthesis, but was 
prepared according to a literature procedure for a similar compound.151,155 3-
Chloroaniline (49) was alkylated through a reductive amination step using acetaldehyde 
and pyridine-borane to yield 3-chloro-N-ethylaniline (55). The final step was performed 
by heating the ethanolic solution of the hydrochloride salt (i.e., 55) at reflux with 
cyanamide to give 53. The desired compound was confirmed by IR spectrometry, 1H 
NMR spectrometry, and elemental analysis for C, H, N. 
 
 
NH
CH3
a HCl N NH2
NHCH3
HCl 
54 52 
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Scheme 5.a 
 
 
 
 
aReagents and conditions: a. acetaldehyde, pyridine-borane, MeOH, reflux; b. HCl/Et2O; 
c. NH2CN, EtOH, reflux. 
 
Three additional compounds (i.e., 56-58), suggested by the obtained results (see 
discussion below), were synthesized. N-(3-Cyanophenyl)-N-methylguanidine nitrate (56) 
was synthesized according to a literature procedure for a similar compound in a one-step 
reaction as described in Scheme 6.154 3-(Methylamino)benzonitrile hydrochloride (59) 
was allowed to react with cyanamide in ethanol. The desired product obtained was 
confirmed by IR, 1H NMR, MS, and elemental analysis for C, H, N. 
Scheme 6.a 
 
 
 
aReagents and conditions: a. NH2CN, EtOH, reflux. 
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Scheme 7 summarizes the synthesis of N-cyclopentyl-N-phenylguanidine 
hydrochloride (57) and N-(3-chlorophenyl)-N-cyclopentylguanidine nitrate (58). The first 
step in the synthesis of these two unknown compounds was a reductive amination 
reaction of aniline (60) and 3-chloroaniline (49), respectively, and cyclopentanone (61) in 
the presence of sodium triacetoxyborohydride (STAB). The hydrochloride salts of the 
obtained compound (i.e., 62 and 63, respectively) were then heated at reflux with 
cyanamide to give 57 and 58 (the former as its hydrochloride salt). An additional step 
was performed to convert the hygroscopic 58 hydrochloride salt to the nitrate salt using 
ammonium nitrate. 
! Scheme 7.a 
 
 
 
 
 
 
 
aReagents and conditions: a. STAB, acetic acid, DCM, room temperature; b. HCl/Et2O; c. 
NH2CN, EtOH, reflux; d. NH4NO3, H2O. 
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B. Biological Data 
 
Our previous findings9 for investigating and optimizing the inhibitory effect of the 
arylguanidines were obtained using the whole-cell configuration of the patch-clamp 
technique on rat α7 nAChRs expressed in stably transfected human embryonic kidney 
(HEK) 293 cells. The number of compounds tested were neither sufficient to identify the 
key physicochemical property for interaction with α7 nAChRs nor enough to decide if the 
N-methyl series binds in a similar or dissimilar manner at α7 nAChRs as MD-354 series.9  
The functional data in the current project were obtained by evaluating the biological 
potencies of the compounds in inhibiting ACh-induced responses in Xenopus laevis 
oocytes expressing human α7 nAChRs using an automated two-electrode voltage-clamp 
assay. Here, the automated system was introduced to overcome several drawbacks 
associated with conventional patch-clamping techniques such as time-consuming issues 
and being very laborious.156 However, recorded potencies of our compounds are expected 
to be lower compared to those from the previously used HEK 293 cells because oocyte 
surface components, such as the large number of invaginations in the membrane and the 
surrounding vitelline membrane and follicle cells, decrease the accessibility of the 
compounds.157 All inhibitory effects measured here were reported in the form of half-
maximal inhibitory concentrations (i.e., IC50 values). Compounds 20-34, 37 and 38 
showed inhibitory action (Table 7) and potency varied over a 10-fold range. 
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Table 7. IC50 values for α7 nAChRs of different structural modifications at the 3-position 
of the MD-354 series and the N-methyl series of arylguanidines. 
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IC50 ± SEM (µM) Compound X Compound IC50 ± SEM (µM) 
     
_59.75  ± 1.21 21 H 25 125.40  ± 1.12 
_41.51  ± 1.24 20 Cl 24 _31.45 ± 1.40 
_23.58  ± 1.08 31 Br 26 _30.23 ± 1.27 
_53.60  ± 6.69 32 F 27 _73.22 ± 1.41 
_21.81  ± 1.24 33 I 28 _12.63 ± 1.41 
_21.29  ± 1.21 22 CF3 37 _31.04 ± 2.82 
118.40  ± 1.97 34 CH3 29 _31.41 ± 1.30 
_40.00  ± 1.44 23 OCH3 30 _57.09 ± 1.98 
X
HN NH2
NH
NH2N
NH
H3C
X
MD-354 (20) 
Series 
N-Methyl (24) 
Series 
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1. QSAR 
 
The chloro group at the 3-position of both MD-354 (20) and 24 was replaced with a 
number of substituents considering the electronic, the lipophilic, and the steric nature of 
the new substituent (Table 7). The introduction of other halogen atoms (i.e., -F, -Br, and 
–I) at the 3-position allowed for testing mainly the effect of substituent-size variation 
over a relatively fixed range of electron-withdrawing effects. Furthermore, replacement 
of the chloro group with -CH3 or -OCH3 groups as electron-donating groups explored the 
effect of such modification on activity. By examining the inhibitory activity of these two 
series of arylguanidine analogs (n = 16) at α7 nACh receptors, we hoped to answer 
multiple questions regarding binding modes of arylguanidines and the impact of parallel 
substituent modifications at the aryl 3-position. The obtained IC50 values showed a range 
of 21 – 118 µM and 12 – 125 µM, respectively (Table 7). Plots for representative 
compounds of these two series (i.e., MD-354 (20) and its N-methyl analog (24)) are 
shown in Figure 21; IC50 of 41.51  ± 1.24 µM and 31.45 ± 1.40 µM, respectively were 
calculated. While removing the chloro group of MD-354 (20) caused a slight reduction in 
potency (i.e., 21, IC50 = 59.75 µM; compared to MD-354 (20), IC50 = 41.51 µM), a more 
pronounced effect of chloro group removal (more than four-fold reduction in potency) 
was seen in the N-methyl series (i.e., 25, IC50 = 125.40 µM; compared to 24, IC50 = 31.45 
µM). Furthermore, the least potent inhibitor in the MD-354 series was the 3-methyl 
analog 34 (IC50 = 118.40 µM) whereas the least potent in the N-methyl series is the 
deschloro analog 25 (IC50 = 125.40 µM). Detailed graphs representing functional data of 
these compounds are shown in Appendix A.  
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To determine if the two series bind in similar manner, we investigated the impact of 
parallel substituent modifications at the aryl 3-position in the two series of analogs. That 
is, if the two series are binding in a common manner, there should be a relationship 
between their potencies. That is, it would be expected that their potencies would co-vary. 
Linear regressions and statistical analyses implemented in this project were conducted 
Figure 21. Concentration/response curves for MD-354 (20) and its N-methyl analog 
(24) (n = 4) inhibition of peak currents elicited by 100 µM ACh at α7 nAChRs.  
!
!
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using GraphPad Prism® software (version 5.04),158 SPSS (Statistical Package for the 
Social Sciences; version 22.0), and JMP (John’s Macintosh Program; version 11.2). 
Correlations expressing a p value of less than 0.05 were considered significant. A poor 
correlation (r = 0.474; n = 8) was found between pIC50 values of the MD-354 (i.e., NH) 
series versus pIC50 values of the N-methyl series (Figure 22). Data on the 3-CH3 analog 
of the N-methyl series (i.e., 29) were replicated and no difference was observed in the 
IC50 value.  Follow-up statistical analysis was conducted to detect any potential outliers 
among the obtained inhibitory potency values using Cook’s D, and Z score methods, 
specifically for the 3-CH3 compounds (Table 8). All IC50 values of the tested compounds, 
including the 3-CH3 analogs, appeared to be within the acceptable range and no single 
value exceeded the cutoffs. Therefore, it is unlikely that the two series are interacting in 
the same manner at α7 nAChRs. This finding supported our previously proposed binding 
modes identified by preliminary docking studies (i.e., as shown in Figure 18). 
  
 
 
 
 
 
 
Figure 22. Plot of pIC50 values of the MD-354 (20) series versus the N-methyl analog 
series (r = 0.474, p = 0.235, n = 8).  
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Table 8. Outlier detection tests and the calculated cut-off values. 
 
 
 
a The Statistical Package for the Social Sciences (SPSS Science, Chicago, IL).  
b John’s Macintosh Program (JMP, SAS Institute Inc., Belmont, Canada). 
 
To analyze the influence of structural features at the 3-position of these compounds to 
act as inhibitors at α7 nACh receptors, Hansch-type QSAR studies were performed 
examining several physicochemical properties of the substituent at the 3-position; π 
(hydrophobic constant),132 σm (Hammett electronic constant),132 Verloop’s steric 
parameters (L, Verloop length; B1, Verloop minimum width; B5, Verloop maximum 
width),159 MR (Molar refraction),160 and solvent accessibility volume (Vol) as calculated 
using Chimera 1.10.1,161 Number of valence electron (NVE),162 Complete molar 
refraction (CMR) as calculated using ChemBioDraw (version 13.0), Molar Volume 
(MV), Parachor value (Pc) as calculated using ChemSketch (version 10.0), and 
polarizability.162 Detailed numerical values of all these physicochemical parameters for 
the currently used substituents are shown in Table 9. Data showed that the action of the 
MD-354 series seemed to be positively correlated with the electronic character (σm) of 
their meta substituent (r = 0.820; n = 8) (Figure 23) and no other correlations were found 
(Table 10). However, the narrow range of IC50 values in this series indicated a need to 
consider additional compounds.
Test Calculated Range Cut-off Software 
Cook’s D 0.00092 – 0.4128 > 0.5 SPSSa 
Zscore -1.6549 – 1.6459 ± 2.5 SPSSa 
Cook’s Influence 0.0182 – 0.4471 > 1 JMPb 
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Table 9. Hansch-type QSAR analysis of the α7 nAChR inhibitory activity of 3-substituted arylguanidines.! 
 
 
 
 
a IC50 data from Table 7. 
b See Table 5 for the description of parameters.  
X IC50 (µM)a πb σmb Lb B1b B5b MRb Volb NVEb CMRb MVb Pcb Polariz.b IC50 (µM)
a X 
H _59.75  ± 1.21 0 0 2.06 1 1 0 122 52 4.08 115 304 15.51 125.40  ± 1.12 H 
Cl _41.51  ± 1.24 0.14 0.34 2.65 1.35 1.35 0.92 126 58 4.1 118 304 15.46 _31.45 ± 1.40 Cl 
Br _23.58  ± 1.08 0.71 0.37 3.52 1.8 1.8 6.03 145 58 4.57 124 333 17.33 _30.23 ± 1.27 Br 
F _53.60  ± 6.69 0.86 0.39 3.82 1.95 1.95 8.88 166 58 4.86 127 347 18.51 _73.22 ± 1.41 F 
I _21.81  ± 1.24 1.12 0.35 4.23 2.15 2.15 13.94 198 58 5.39 132 367 20.53 _12.63 ± 1.41 I 
CF3 _21.29  ± 1.21 0.88 0.43 3.3 1.98 2.61 5.02 151 76 4.59 145 358 17.39 _31.04 ± 2.82 CF3 
CH3 118.40  ± 1.97 -0.02 0.12 3.98 1.35 3.07 7.87 146 64 4.7 137 354 17.81 _31.41 ± 1.30 CH3 
OCH3 _40.00  ± 1.44 0.56 -0.07 2.87 1.52 2.04 5.65 138 58 4.54 130 335 17.26 _57.09 ± 1.98 OCH3 
NH NH2
NH
X
NH3C NH2
NH
X
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Table 10. Summary of the linear regression analysis results for MD-354 series (n = 8). 
Equation 
No. QSAR Equation for pIC50 r F p 
1 0.9700 (± 0.5705) π -3.732 (± 2.511) 0.570 2.89 0.140 
2 0.6194 (± 0.1763) σm -2.481 (± 0.7762) 0.820 12.34 0.012 
3 1.851 (± 0.8862) L -4.830 (± 3.901) 0.648 4.36 0.081 
4 1.075 (± 0.4440) B1 -3.088 (± 1.954) 0.703 5.86 0.052 
5 0.9364 (± 0.9639) B5 -2.119 (± 4.243) 0.368 0.94 0.369 
6 9.317 (± 5.899) MR -34.91 (± 25.97) 0.541 2.49 0.165 
7 64.89 (± 27.64) Vol -136.2 (± 121.7) 0.691 5.51 0.057 
8 12.93 (± 9.965) NVE +3.413 (± 43.86) 0.468 1.68 0.242 
9 0.9616 (± 0.5335) CMR +0.3771 (± 2.348) 0.592 3.25 0.121 
10 17.49 (± 13.79) MV +51.62 (± 60.69) 0.459 1.61 0.252 
11 57.77 (± 29.11) Pc +83.82 (± 128.1) 0.629 3.94 0.094 
12 3.694 (± 2.085) Polarizability +1.238 (± 9.178) 0.586 3.14 0.127 
 
 
 
 
 
 
 !
Figure 23. Plot of pIC50 values of the MD-354 (20) series versus the electronic 
character (σm) (r = 0.821, p = 0.012, n = 8).  
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On the other hand, a significant positive correlation was found between pIC50 values of the 
N-methyl series compounds with their lipophilic nature (π) (r = 0.912; n = 8) and their minimum 
width (Verloop B1) (r = 0.927; n = 8) (Figure 24A and B, respectively) (Table 11). These two 
parameters gave the best-fitting models that are supported by the highest F values (Table 11). 
This suggests the importance of these physicochemical properties at the 3-position of the N-
methyl series. However, a significant internal correlation exists between the two properties (r = 
0.956; n = 8) (Figure 25). Detailed correlation plots of all these physicochemical parameters for 
the currently used substituents in the N-methyl series are shown in Appendix B. 
 
Table 11. Summary of the linear regression analysis results for N-methyl (i.e., 24) series (n = 8). 
Equation 
No. 
QSAR Equation for pIC50 r F  p 
13 1.326 (± 0.2431) π -5.303 (± 1.072) 0.912 29.74  0.001 
14 0.2923 (± 0.2348) σm -1.045 (± 1.035) 0.453 1.55  0.260 
15 1.860 (± 0.6427) L -4.883 (± 2.835) 0.763 8.38  0.030 
16 1.211 (± 0.2000) B1 -3.693 (± 0.8819) 0.927 36.68  0.001 
17 0.9730 (± 0.7918) B5 -2.286 (± 3.492) 0.448 1.51  0.265 
18 12.85 (± 2.902) MR -50.53 (± 12.80) 0.875 18.61  0.021 
19 70.71 (± 15.37) Vol -162.2 (± 67.81) 0.882 12.16  0.013 
20 6.216 (± 9.293) NVE +32.89 (± 40.99) 0.263 0.44  0.528 
21 1.238 (± 0.2545) CMR -0.8450 (± 1.123) 0.893 3.24  0.122 
22 17.57 (± 11.16) MV +51.17 (± 49.21) 0.540 2.48  0.166 
23 63.14 (± 18.97) Pc +59.83 (± 83.65) 0.805 11.08  0.023 
24 4.794 (± 1.001) Polarizability -3.625 (± 4.416) 0.890 9.87  0.016 
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Figure 24. Plot of pIC50 values of the N-methyl series versus A) the Verloop minimum 
width (B1) (r = 0.927, p = 0.001, n = 8) and B) the hydrophobic constant π (r = 0.912, p 
= 0.001, n = 8). 
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Based on the above QSAR studies, there appears to be dissimilar binding modes for the two 
series of compounds at α7 nAChRs (i.e., structure-activity results for one series cannot be 
applied to the other). Among the examined physicochemical properties, only electronic character 
appeared to play a role at the 3-position of the MD-354 series for α7 nAChR action; however, 
more compounds are required to substantiate this. For the N-methyl series, two major factors 
appear to be involved as important structural features at that position for α7 nAChR action (i.e., 
lipophilic nature and the minimum width of the substituent). Due to a significant intercorrelation 
between the two parameters examined for the current data set (i.e., between π and Verloop B1), it 
was not possible to identify a single parameter as being the more important. Consequently, it was 
of interest to synthesize an additional compound in this series that clarifies uncertainty associated 
Figure 25. Plot describing the internal correlation between the hydrophobic 
constant (π) and Verloop minimum width (B1) (r = 0.956, p = 0.0016, n = 8). 
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with the importance between these two parameters. Thus, the next candidate compound to be 
synthesized and tested was the 3-CN analog (56) since it provides a high Verloop minimum 
width value (B1 = 1.6) and low lipophilic character (π  = -0.57). According to Equation 13 
(Table 11), if the hydrophobic character is the most important physicochemical property, the IC50 
value will be 0.873 µM. Whereas, if the minimum width property is the most important 
physicochemical parameter, the IC50 value, according to Equation 16, will be 17,563 µM.  
From this point, our efforts will only consider the N-methyl series for further investigation. 
The MD-354 series is not of particular interest due to selectivity reasons since these compounds 
bind reasonably well at 5-HT3 receptors.  
 
 
2. Topliss Tree 
 
The above QSAR analysis of the N-methyl series of aryl guanidines focused on investigating 
the effects of various substituents at the aryl 3-position. The Topliss-decision tree approach 
allows an investigation of the lipophilic effect at the N1 position. The necessity of introducing the 
N-isopropyl pairs was also to test whether or not the two series of compounds (i.e., the chloro 
and the deschloro compounds) interact with α7 nACh receptors in a similar manner depending 
on the fold-difference in biological data obtained. The examination of inhibitory action of a fixed 
concentration (i.e., 10 µM) of compounds 20, 21, 24, 25, 38, and 39 at α7 nACh receptors 
resulted in a different extent of inhibition compared to the normalized current evoked by ACh at 
its EC50 concentration (Figure 26). Incorporation of the N-isopropyl group as seen in 39 not only 
!
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increases lipophilicity but adds extra steric bulk that appears to be not as well tolerated as the N-
methyl group in 24. Results also showed that the introduction of an isopropyl group in 38 seems 
to result in retention of inhibition potency at α7 nAChRs. The new isopropyl analogs appear to 
have less selectivity and can inhibit α3β4 nAChRs, especially the 3-chloro compound 39 (Figure 
26). Furthermore, it seems that there is a non-parallel inhibitory effect between the chloro-
deschloro pairs of compounds indicating either possible different binding modes or distinct 
binding sites for the two series. This suggests that the introduction of an ethyl group (i.e., 52, and 
53 for the deschloro and chloro analogs, respectively) might optimize the effect, especially for 
the chloro series (20, 24, and 39). 
 
 
 
 
 
 
 
Figure 26. Effect ± SEM of 20, 21, 24, 25, 38, and 39 at 10 µM concentration on ACh 
function at α7 (ACh EC50 = 280 µM; red bars) and α3β4 (ACh EC50 = 100 µM; blue 
bars) nAChRs relative to ACh (normalized current = 1). 
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The IC50 values obtained later showed different inhibition patterns of these compounds on α7 
nAChR function (Table 12). Replacing the methyl group in 24 with isopropyl (i.e., 39) caused a 
slight improvement in potency. Removing the chloro group of 39 (i.e., 38) caused no effect on 
potency (Table 12). The most dramatic effect of chloro group removal (more than four-fold 
reduction in potency) was seen in the N-methyl series (i.e., 25, IC50 = 125.40 µM; compared to 
24, IC50 = 31.45 µM). Furthermore, although it is perhaps premature to draw definitive 
conclusions, when comparing antagonist potency of the two pair of compounds 20, 21 in the 
guanidine series and 24, 25 in the N-methyl series, the data suggest that the two series of 
compounds might bind in a different manner because parallel structural modifications did not 
result in a parallel shift in activity (Figure 26). That is, removal of the 3-Cl group in the 
guanidine series resulted in a ca. 5-fold decreased potency whereas in the N-methyl series it was 
ca. 25-fold. If the compounds were binding in the same manner, the shift in activity might be 
expected to be of the same magnitude. However, additional compounds are needed to support 
such an assumption and the next candidate compounds, according to Topliss tree approach, are 
the deschloro and the 3-chloro analogs of N-cyclopentyl-N-phenylguanidine (i.e., 57 and 58, 
respectively).163 
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Table 12. IC50 values at α7 nAChRs for arylguanidines with different structural modifications at 
the N1 and 3-positions. 
 
 
 
 
 
 
 
 
 
3. Role of Nitrogen Atoms 
 
The purpose here was to develop an understanding of the role of the guanidine moiety in 
arylguanidine inhibitory actions at α7 nAChRs. We investigated the effect of alkylating one or 
more of the guanidine nitrogen atoms, and the necessity of the presence of these nitrogen atoms 
in our compounds for their inhibitory action. With respect to the arylguanidines, it is already 
known that the introduction of a methyl group at the aniline nitrogen of MD-354 (20) (i.e., 24) 
Compound R X IC50 ± SEM µM 
21 H H 59.75 ± 1.21 
20 H Cl 41.51 ± 1.24 
25 CH3 H 125.40 ± 1.12 
24 CH3 Cl 31.45 ± 1.40 
52 C2H5 H 39.84 ± 1.07 
53 C2H5 Cl 26.92 ± 1.07 
38 CH(CH3)2 H 19.78 ± 1.35 
39 CH(CH3)2 Cl 21.89 ± 1.42 
NR NH2
NH
X
!
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improved both potency and selectivity at α7 nAChRs. The incorporation of a methyl group at the 
terminal nitrogen atom (i.e., 40; IC50 = 22.07 µM) resulted in a slight improvement in potency 
compared to MD-354 (20, IC50 = 41.51 µM); however, this modification is detrimental to the 
inhibition efficacy since the dose-response curve does not show a complete inhibition of the ACh 
response at high concentrations (Figure 27A). Furthermore, replacement of the aniline NH by a 
methylene group (i.e., 41), or removing one of the terminal nitrogen atoms of 41 (i.e., 3-
chlorophenylethylamine; 42) resulted in retention of potency relative to MD-354 (20), 
respectively, at α7 nACh receptors (Figure 27B and C). The replacement of one of the two 
terminal nitrogen atoms with a carbonyl oxygen atom (i.e., 3-chlorophenylurea; 43; EC50 = 365.9 
µM) resulted in an activator molecule for α7 nAChRs (Figure 27D).  
From the tested compounds reported in the above data, it would seem that not all of the 
nitrogen atoms are required for activity at α7 nAChRs. This observation, however, requires 
further testing to determine the mechanism of inhibition (i.e., competitive or non-competitive 
inhibition) and the mode of binding of these compounds at the molecular level. That is, these 
provide multiple means to block the actions of ACh. These analogs might produce their action by 
binding at the orthosteric site, a different allosteric site (other than that to be described in the next 
section) and/or as channel blockers. However, these findings open new avenues for future 
investigation. 
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Figure 27. Plot of IC50 curves for 40 (A), 41 (B), and 42 (C) in µM at α7 nAChRs (ACh 
concentration is 100 µM). Compound 43 (D) showed weak agonist activity at α7 
nAChRs.  
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C. Molecular Modeling 
 
1. Sequence Alignment and Homology Modeling  
 
Homology modeling studies were used to address a number of questions regarding the 
potential binding site(s) and the mode of interactions that explain the functional activity of our 
compounds at α7 nAChRs. All primary sequences used in our alignment were obtained from the 
Universal Protein Knowledgebase (UniProtKB). Multiple alignments of the human α7 nAChR 
sequence with several orthologs were performed using ClustalX 2.0 and key amino acid residues 
were determined (Figure 28 and 29). Furthermore, these alignments were established to identify 
and match conserved residues between the human α7 nAChR and the template, the X-ray crystal 
structure of a chimeric ECD of a human α7 nAChR and an Lymnaea stagnalis acetylcholine 
binding protein (AChBP) (PDB ID 3SQ6) that shares 64% sequence identity with the ECD of the 
human α7 nAChR ECD, the NMR structure of the TMD of the α4 nAChR subunit (PDB ID 
2LLY) that shares 49% sequence identity with the TMD of the human α7 nAChR, and the cryo-
electron microscopy structure of Torpedo marmorata nAChR (PDB ID 2BG9) that shares 53% 
sequence identity with the TMD of the human α7 nAChR.  
Through aligning the primary sequence of the ECD of the human α7 nAChR with the 
template, important regions in the aligned sequences were identified including the loops A, B, C, 
D, E, and F that primarily formed the orthosteric binding sites in these receptors (Figure 28). 
Furthermore, the two cysteine residues (i.e., Cys150 and Cys164) forming the disulfide bond 
characterizing the Cys-loop, and the adjacent two cysteine residues (Cys212 and Cys213) 
forming the disulfide bond at the C loop were also matched. The advantage of using the primary 
!
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sequence of the chimeric ECD of the α7 nAChR (PDB ID 3SQ6) can be seen through the 
presence of many amino acids that are highly conserved with the human α7 nAChR sequence. 
Other important amino acids are Val220, Thr221, and Phe222 that are known to interact with α7 
nAChR PAM galantamine (13).70 
 
 
Sequence alignments of the TMDs of the α7 nAChRs and the templates used revealed a low 
degree of similarity compared to the ECDs alignments. Important regions in the aligned 
sequences were identified which included Glu237 and Glu258 at the ends of M2, the amino acids 
responsible in forming the upper and lower rings within the pore of the α7 nAChR (Figure 29).25 
Other identified residues include Ser222 and Ala225 from M1, Met253 from M2, Gln272 from 
M3, and Phe455, Thr456 and Cys459 from M4 that are known to have essential interactions with 
two α7 nAChR PAMs, PNU-120596 (15) and ivermectin (16).80 
Figure 28. Sequence alignment of the ECD portion from the human α7 nAChR and α7 
nAChR chimera. The asterisks (*) indicate conserved amino acids, whereas the colons 
(:) and periods (.) indicate strongly and weakly conserved amino acids, respectively. The 
colored lines represent the main loops in the ECD. The red box indicates the galantamine 
binding site as shown by Ludwig et al.70 
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Construction of 100 homology models was accomplished in the form of dimers of the human 
α7 nAChR ECD and in the form of monomers of the TMD using Modeller 9.12.  Dimer 
formation provided the essential part of the ECD for the molecular modeling study since α7 
nACh receptors are homomeric and the orthosteric binding site is located between each two 
subunits. The three-dimensional structures of 100 models of each domain were energetically 
evaluated based on DOPE (Discrete Optimized Protein Energy) scores. A subsequent validation 
step was performed by the docking of α7 nACh receptor modulators (i.e., galantamine (13) for 
the ECD, and PNU-120596 (15) and ivermectin (16) for the TMD).  
Figure 29. Sequence alignment of the TMD portion of nAChRs from three species. The 
asterisks (*) indicate conserved amino acids, whereas the colons (:) and periods (.) 
indicate strongly and weakly conserved amino acids, respectively. The four main TMDs 
are represented by the turquoise lines. The red box indicates important amino acid 
residues interacting with either PNU-120596 or ivermectin as shown in Young et al.74 
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2. Crystal Structures of Guanidines 
 
In the PDB archive, we found that guanidine-containing ligands have common patterns in 
their interactions with macromolecules. The protonated form of guanidines (i.e., the guanidinium 
group) is the common form at physiological pH, which suggests their potential involvement in 
electrostatic interactions.144,145 In most cases, guanidinium groups were found to form bidentate 
interaction with the side-chain carboxylate of aspartate amino acids (i.e., 1 and 3-5; Table 13).144-
146 The orientation of the guanidine-containing ligands, in some cases, restricted the bidentate 
form, so that only one ionic hydrogen bond instead of two was formed with the side-chain 
carboxylate of aspartate and glutamate amino acids (i.e., 2, 6, and 7; Table 13).146 Guanidinium 
groups, also, are able to form hydrogen bonds with the side-chain hydroxyl groups of serine 
residues (i.e., 1-3; Table 13) and with the backbone oxygen atoms of amino acids (i.e., 1-6, and 
8; Table 13).144-148 
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Table 13. Summary of interactions of guanidinium groups in guanidine-containing ligands from 
the PDB database. 
 
1) PDB ID: 1S6F 
 
 
2) PDB ID: 1S5S 
 
 
3) PDB ID: 2VNT 
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5) PDB ID: 1ZML 
 
6) PDB ID: 1ZMN 
 
 
7) PDB ID: 3PO1 
 
8) PDB ID: 3HPT 
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3. Allosteric Binding Site Exploration  
 
 
Eight putative allosteric binding pockets for the small-molecule NAMs of α7 nAChRs were 
initially identified, through cavity-search studies conducted with the Connolly surface feature of 
SYBYL-X 2.1 and the blind docking feature of AutoDock 4.2 at the α7 nAChR model. Initial 
findings indicated the presence of five cavities at the ECD and three cavities at the TMD (I-VIII; 
Figure 30). The five cavities found in the ECD are in agreement with the previously reported 
work of Iorga et al.126 (ECD upper exterior site (I), the orthosteric site (II), ECD-lower exterior 
site (III), ECD-upper interior site (IV), and ECD-lower interior site (V); Figure 30A and B). 
Further evaluation of these potential binding pockets was performed to exclude cavities that 
violate logical standards. Prior knowledge that both MD-354 (20) and 24 are not competitive 
antagonists and not channel blockers led to the elimination of three cavities (i.e., the orthosteric 
site (II), ECD-upper interior site (IV), and ECD-lower interior site (V)). Also, the ECD-upper 
exterior site was eliminated from consideration due to limited cavity volume (i.e., 123 Å3 
compared to 145 Å3 and 161 Å3, the molecular volume for 20 and 24, respectively). This 
suggested that the ECD-lower exterior site is the only ECD site candidate for our modeling and 
docking studies. 
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Figure 30. A and B represent side views of the modeled ECD of the human α7 nAChR 
dimer showing the location of allosteric cavities I-V at the exterior and interior surfaces, 
respectively. C represents top view of the TMD showing the location of allosteric 
cavities VI-VIII. 
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Similarly, the three TMD cavities (i.e., TMD intrasubunit site (VI), TMD exterior site (VII), 
TMD interior site (VIII); Figure 30C) were analyzed. These cavities were in agreement with 
reported computational work of Brannigan et al.129 on possible binding pockets of the anesthetic 
isoflurane in nicotinic receptors. Both the TMD exterior site and TMD interior site were 
eliminated due to limited cavity volume (i.e., 116 Å3) and the channel blocking problem, 
respectively. This makes the TMD intrasubunit site the most likely TMD site candidate for our 
modeling and docking studies. 
The two identified binding pockets (i.e., the ECD-lower exterior site (III) and the large TMD 
intrasubunit cavity (VI)) are known to be the binding site for α7 nAChR modulators. For 
example, galantamine (13) is an α7 nAChR PAM that interacts at the ECD-lower exterior site 
(III), whereas ivermectin and PNU-120596 are two α7 nAChR PAMs that interact in distinct 
locations at the general TMD intrasubunit cavity. This fact led us to target three different 
locations; one at the ECD characterized by amino acid residue Thr221 and two in the TMD 
intrasubunit cavity that are characterized by amino acid residues Met253 (i.e., the key amino acid 
for ivermectin binding) and Ser222 (i.e., the key amino acid for PNU-120596 binding). All these 
key residues were determined using the reported mutagenesis data70,74 that were discussed above. 
 
4. Docking Studies and Hydropathic Analyses 
 
Within SYBYL-X 2.1, four low-energy rotamers of arylguanidine analogs were 
computationally prepared for docking. Molecular docking was conducted using the CHEMPLP 
scoring function (within the genetic algorithm docking program GOLD 5.2) and the docking 
solutions were analyzed (SYBYL-X 2.1). The binding site was defined to include all atoms 
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within 10 Å of the α-carbon atom of the key amino acid residue for the candidate homology 
models. Based on the fitness scores and the binding orientation of each ligand within the binding 
cavity, the best-docked solution was selected and merged into the receptor. Energy minimization 
was carried out using the Tripos Force Field to optimize the interactions between ligand and 
receptor within the binding pocket, followed by PROCHECK and ProTable analyses to validate 
the candidate models. 
The optimized model-ligand complexes were then rescored with the HINT program (Table 
14) in order to compare and contrast different binding pockets. Further evaluation of HINT 
scores was performed using Boltzmann analysis (Table 14). Hydropathic analyses of the data 
indicated an energetic preference (the larger the positive number the more energetically 
preferable) of the interaction of 20 and 24 at the ECD (917 and 627, respectively) allosteric site 
over the TMD site (-390 and 251 , respectively, for TMD site characterized by Met253 and 129 
and 273 , respectively, for TMD site characterized by Ser222). The Boltzmann-weighted score in 
the score population for 20 and 24 at the ECD are 417 and 645, respectively, whereas Boltzmann 
values for 20 and 24 at the TMD site characterized by Met253 are -639 and -386, respectively. 
Boltzmann values for 20 and 24 at the TMD site characterized by Ser222 are -174 and -62, 
respectively. 
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Table 14. Summary of HINT and Boltzmann scores for the interactions of MD-354 (20) and its 
N-methyl analog 24 at the two (i.e., the ECD and TMD) putative binding sites. 
 
 
 
 
 
 
 
 
Different possible binding modes were suggested in our docking studies for 20 and 24 as 
depicted in Figure 31. MD-354 (20) appears to utilize a binding mode at which N1 and N2 form 
an ionic bond with Asp219 and possible hydrogen bonds with Ser206 and Thr221 (Figure 31A). 
Furthermore, the same part of the guanidine moiety appeared to form a hydrogen bond with 
Lys204, Ser206 and Asp219 amino-acid backbone oxygen atoms. The chloro group of 20 
displayed Van der Waals interactions with the side chains of Pro202 and Lys204, and the 
backbone of Gly203 (not shown) connecting these two amino acid residues from one side, and a 
possible hydrogen bond with Thr223. In contrast, the N1-methyl analog 24 utilized the N2 and N3 
atoms to form an ionic bond with Asp219 and possible hydrogen bonds with Ser206 and Thr221 
(Figure 31B). In addition, the same part of the guanidine moiety appeared to form a hydrogen 
bond with Asp219 and Ser206 amino-acid backbone oxygen atoms. The terminal N of Lys165 
 Site 3 Site 6 
 ECD (Thr221) TMD (Ser222) TMD (Met253) 
Hint 627 [-1.22] 273 [-0.53] 251 [-0.49] 
Boltzmann Av. 417 [-0.81] -62 [0.12] -386 [0.75] 
 Site 3 Site 6 
 ECD (Thr221) TMD (Ser222) TMD (Met253) 
Hint 917 [-1.78 ] 129 [-0.25] -390 [0.76] 
Boltzmann Av. 645 [-1.25] -174 [0.34] -639 [1.24] 
HN NH2
NH
Cl
NH3C NH2
NH
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seemed to form a possible cation-π interaction with the phenyl ring of 24. The chloro group of 24 
displayed Van der Waals interactions with the side chains of Pro202 and Lys204, and the 
backbone of Gly203 (not shown) connecting these two amino acid residues from one side, and a 
possible hydrogen bond with the Thr223. The two distinct models (Figure 31) are consistent with 
the functional data and in agreement with the common patterns of interactions of guanidine-
containing ligands in the PDB archive (Table 13). 
 
 
 
 
 
 
 
 
 
 
 
!
!
!
!
103!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. A and B represent the binding modes of MD-354 (20) and 24 in the ECD allosteric 
site III of α7 nAChRs, respectively, and are depicted by the schematic representation in the 
upper right corner (where D = Asp, aspartate). The lower right corner represents the 
alignment of the orientation of both molecules.  
A 
B 
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HINT contour maps, which contain hydrophobic/polar fields and acid/base fields, were 
generated as another useful visualization of the above interactions of 20 and 24 with amino acids 
at the binding site (ECD site III; Figure 32). The obtained data define the extent of polar and 
hydrophobic intermolecular forces contained in the total scores obtained at each site (positive 
values imply favorable interactions while negative values denote disfavorable interactions). Both 
20 and 24 show more polar interactions at the ECD site compared to both TMD sites. 
  
 
 
Location Molecule Total Polar Hydrophobic 
Site III 
 (Thr221) 
20 917 1267 -350 
24 627 908 -281 
Site VI 
 (Ser222) 
20 129 202 -73 
24 273 446 -173 
Site VI 
 (Met253) 
20 -390 224 -618 
24 251 -27 278 
A B 
Figure 32.  HINT contour maps for the plausible binding site of MD-354 (20) and 24 
showing a polar area (blue and red) and a hydrophobic area (green).  
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D. Pharmacophore for Arylguanidines as α7 nAChR NAMs 
 
In comprehensive reviews, Glennon, and Dukat164-166 discussed development of nAChR 
pharmacophores from an historical perspective to the more recent α4β2 nAChR pharmacophores. 
Briefly, the first attempt to determine the ligand features necessary for nicotinic cholinergic 
activity was in 1952 when Hey defined two structural features, a quaternary amine separated by a 
suitable distance from a partial positively-charged atom.164-166 In 1962, Barlow and Hamilton 
estimated this distance to be 3.4 to 3.5 Å.164,165 A partial negatively-charged atom was also 
reported by Holland and co-workers to be required in addition to the quaternary amine.164,165 In 
1968, Kier reported an optimal distance of 4.85 Å between the quaternary amine and the partial 
negatively-charged atom.164 A specific pharmacophore model for nAChR ligands was reported in 
1970 by Beers and Reich.165-167 The model indicated that the specific binding of nicotinic 
agonists to nAChRs is mediated by an electrostatic interaction between a positively-charged 
nitrogen atom, and a hydrogen bond from an electronegative atom such as a carbonyl oxygen 
atom or a nitrogen atom. Since that time, several publications about the pharmacophore showed 
other details for the structural requirements of nAChR orthosteric ligands, such as a cationic 
center, an electronegative atom capable of forming a hydrogen bond, and the center of a 
lipophilic region (e.g., pyridine ring in (-)-nicotine (1)).168 Most of these studies were for 
peripheral nAChRs or for neuronal α4β2 nAChRs.168,169 And, since then, other types of nAChRs 
have been identified.  
A pharmacophore model specifically for α7 nAChR orthosteric ligands, generally, fits the 
classical three nAChR pharmacophoric elements (i.e., a cationic center, an electronegative atom 
capable of forming a hydrogen bond, and a lipophilic center; Figure 33).170,171 However, some 
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refinements of this model were reported in order to achieve subtype selectivity using α7 nAChR-
selective anabaseine analogs (e.g., GTS-21 (8)) and other α7 nAChR-selective N,N-
dialkylpiperidine compounds.172 The refined model indicated a secondary (relatively small) 
hydrophobic pocket that exists in the binding site of α7 nACh receptors closer to the charged 
nitrogen pharmacophoric element (Figure 33).  
On the other hand, there have been few previous attempts to determine a pharmacophore 
model specifically for α7 nAChR allosteric ligands. For example, a small set of phthalazinone, 
pyridazinone, and quinazoline compounds was identified through screening to possess high 
potency as α7 nAChR PAMs.173 Compelling molecular modeling studies suggested that all three 
classes of compounds display a common binding mode.173 Although some of the compounds 
tested in this study were known to bind at the TMD allosteric site of α7 nAChRs (i.e., TMD 
intrasubunit site (VI); Figure 30),171,173 no single compound has been reported to act at the 
galantamine binding site (i.e., the ECD-lower exterior site (III); Figure 30). The authors 
proposed a pharmacophore model consisting of a hydrogen bond donor, a hydrogen bond 
acceptor, and three hydrophobic regions for the molecule in order to fit the proposed model 
(Figure 34).173 To date, no NAM pharmacophore for α7 nAChR ligands  has been reported. 
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Figure 33.  A pharmacophore model that confers selectivity for the α7 nAChR orthosteric 
binding site. An analog of GTS-21 is embedded in the center of the model where the blue 
lines indicate the classical α7 nAChR ligand pharmacophore, and the red line represents the 
additional features for selective α7 nAChR ligands (adapted from Leonik et al.172 and 
Lightfoot et al.174). 
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Figure 34.  A pharmacophore model for α7 nAChR PAMs. A quinazoline compound is 
embedded in the center of the model where the blue lines indicate the pharmacophoric 
elements at α7 nAChR allosteric sites (adapted from Capelli et al.173). 
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Here, we attempted to define a pharmacophore for small-molecule arylguanidine NAMs at 
α7 nAChRs using comparative molecular field analysis (CoMFA; an auxiliary set in SYBYL-X 
2.1 used to assess 3D-QSAR). Our assumption here was that the compounds used in this study 
might or might not interact in a similar manner at the site that we proposed, according to our 
hydropathic analysis, to be most likely the ECD-lower exterior site (III) (Figure 30). CoMFA 
provides an assessment of the relationship between electrostatic and steric interactions, and 
biological activity, toward the determination of significant structural features within a group of 
compounds. This was accomplished in two steps. First, we examined the entire set of 
arylguanidines as a whole (n = 19). Next, we examined the two sets individually (i.e., the MD-
354 (20) or the aniline NH series, and the N-alkyl series, n = 7 and 12, respectively) 
In our initial CoMFA run, we used the molecular conformation of each molecule as observed 
in our docking solutions. Although CoMFA studies showed a high cross-validated r2 (q2) value 
of 0.88 for the aniline NH series (n = 7) (i.e., 20-23, and 31-33; Table 7), it showed a low 
predictive value of 0.02 and 0.01 (the predictability should be higher than 0.6 in order for the 
model to be valid) for the whole arylguanidines set of compounds (n = 19) (i.e., 20-33, 37-39, 
52, and 53; Table 7 and 12) and the N-alkyl series (n = 12) (i.e., 24-30, and 37; Table 7), 
respectively. In a second run of CoMFA, all structures of the arylguanidines were manually 
aligned (i.e., three non-linear points: the aromatic centroid, the cationic carbon and the meta 
substituted carbon) to the most common conformations observed in our docking solutions. The 
highest cross-validated r2 (q2) obtained by our CoMFA studies for the whole arylguanidine set of 
compounds (n = 19) was 0.43, whereas the highest q2 value was -0.40 for the N-alkyl series (n = 
12). The q2 value for the aniline NH series (n = 7) using manual alignment was similar to what 
was obtained previously in the first CoMFA run (q2 = 0.88). 
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In a third CoMFA run, we applied GASP175 (genetic algorithm similarity program; an 
unbiased alignment algorithm implemented in SYBYL-X 2.1) to our compounds (i.e., 20-33, 37-
39, 52, and 53; Table 7 and 12) in order to perform the alignment step (Figure 35A). GASP-
guided alignments for all nineteen compounds were then used for our CoMFA studies. The 
significance of each CoMFA model was indicated by a cross-validated r2 (q2) value that showed 
a low predictive value of -0.36 for the nineteen arylguanidine compounds [seven compounds 
(20-23, and 31-33; Table 7) from the MD-354 (20) series (i.e., all the currently investigated 
analogs except the 3-CH3 analog due to uncertainty of its experimental results), eight compounds 
from the N-methyl series (24-30, and 37; Table 7), and four compounds representing the chloro 
and deschloro analogs of the N-ethyl and N-isopropyl compounds (38, 39, 52, and 53; Table 
12)]. The results above indicated the possible lack of a common pharmacophore model for the 
nineteen arylguanidine compounds due to the weak q2 values (CoMFA map is not shown).  
GASP-guided alignments were also performed for the two individual sets of compounds. The 
seven compounds (i.e., 20-23, and 31-33; Table 7) of the MD-354 (or NH) series were used for 
GASP alignment (Figure 35B) and the results showed the possibility of a hydrogen bond being 
formed (i.e., AS1) compared to the twelve compounds (i.e., 24-30, 37-39, 52, and 53; Table 7 
and 12) representing the N-alkylated series (Figure 35C) where the AS1 hydrogen bond was 
absent.  
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Figure 35.  Alignment of the molecules using GASP for the nineteen analogs (i.e., 20-
33, 37-39, 52, and 53) (A), the seven analogs representing the MD-354 series (i.e., 20-
23, and 31-33) (B), and the twelve analogs representing the N-alkylated series (i.e., 
24-30, 37-39, 52, and 53) (C) showing hydrogen bond Acceptor Sites (AS), and 
HYdrophobic centers (HY) (yellow circles), and hydrogen bond Donor Atoms (DA).  
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CoMFA studies showed a cross-validated r2 (q2) value for the seven compounds in the NH 
series (i.e., 20-23, and 31-33; Table 7) of 0.78 (r2 = 0.98, SE = 0.036, number of components is 
2) (Figure 36A). These results suggested that the model for the MD-354 (i.e., aniline NH series) 
is dominated by a steric component, which explains about 91% of the variation in pIC50 at α7 
nAChRs. The r2 of 0.98 for the model indicated a good correlation with pIC50 values. 
The cross-validated r2 (q2) value for the twelve compounds (i.e., 24-30, 37-39, 52, and 53; 
Table 7 and 12) representing the N-alkylated series was 0.44 (r2 = 0.95, SE = 0.07, number of 
components is 4). This marginal value of q2 was improved to 0.60 when the number of 
components was increased to 5 (r2 = 0.98, SE = 0.04) (Figure 36B). The model was dominated 
by a steric component, which explains about 84% of the variation in pIC50 at α7 nAChRs. The r2 
value of 0.98 for the model indicated a robust correlation with pIC50 values.  
These results support our previous conclusion of possible different binding modes between 
the two series (i.e., the MD-354 or NH series, and the N-alkylated series). That is, using an 
unbiased GASP alignment, CoMFA failed to account for the action of the entire series of 
nineteen compounds to behave as NAMs at α7 nAChRs. However, when examined separately, 
the two series, that is, the MD-354 (or NH) series, and the aniline N-alkyl series, allowed the 
identification of pharmacophore features. Overall, these studies support our other findings that 
the NH and N-alkyl series bind in a different manner. 
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The N-alkyl arylguanidine series compounds appear to adopt a common binding mode, and 
this differs from that of the MD-354 (i.e., NH) series in that the latter possesses five hydrogen 
bonding sites, whereas the former only possesses four (see Figure 35B and 35C, respectively). 
The model indicates the need for four hydrogen bond components and a hydrophobic region for 
the molecule in order to fit the proposed pharmacophore model (Figure 37). 
Figure 36.  CoMFA maps for the seven analogs (i.e., 20-23, and 31-33) representing the MD-
354 series (A) (n = 7, q2 = 0.78, r2 = 0.98; number of components = 2; 90.7% steric and 9.3% 
electrostatic) and the twelve analogs (i.e., 24-30, 37-39, 52, and 53) representing the N-
alkylated series (B) (n = 12, q2 = 0.60, r2 = 0.98; number of components = 5; 84.6% steric and 
15.4% electrostatic). Green regions representing bulky substituents are favored, whereas the 
yellow regions representing bulky substituents are disfavored. Blue regions represent 
positively charged substituents are favored.  
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There are some shortcomings associated with our CoMFA studies (i.e., the relatively small 
set of compounds and the narrow range of IC50 values). It should be kept in mind that all the 
compounds were arylguanidines. Compounds such as the 3-chlorophenylethylamine (42), if it is 
ever shown to be a NAM, can influence the pharmacophore. Nevertheless, the results suggest 
new compounds that can be proposed, synthesized, and evaluated.176 
Figure 37 describes the first pharmacophore model for N-alkyl arylguanidines as α7 nAChR 
NAMs. It is rather interesting that the model lacks a hydrogen bond feature associated with the 
anilinic nitrogen atom, a feature found in the MD-354 (or anilinic NH) model (see Figure 35B). 
Because Dukat177 has previously proposed an anilinic NH as being important for binding of 
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Figure 37.  A pharmacophore model for N-alkyl arylguanidine α7 nAChR NAMs. A 
generalized N-alkyl arylguanidine is embedded in the center of the model where the 
blue lines indicate the pharmacophoric requirements at α7 nAChR allosteric sites as 
suggested by our pharmacophore study. 
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arylguanidines at 5-HT3 receptors, the lack of this feature might account for the greater α7 
nAChR selectivity of the N-alkyl arylguanidines over the NH arylguanidines.  
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V. Conclusions 
 
 
 
A number of compounds based on MD-354 (20) and its N-methyl analog 24 were 
synthesized and evaluated for their activity as inhibitors at α7 nACh receptors. MD-354 was 
initially developed as a 5-HT3 receptor agonist earlier in our laboratory and has been found to be 
the first example of a small-molecule NAM of α7 nAChRs. Our previous studies showed that the 
incorporation of an N1-methyl substituent into arylguanidine led to compounds with enhanced 
selectivity as NAMs of α7 nACh receptors. This indicated that the two actions can be divorced 
and that removing structural features required for 5-HT3 receptor binding also resulted in 
enhancement of α7 nACh receptor NAM potency. The N-methyl analog of MD-354 (i.e., 24) 
showed 177-fold lower affinity than 20 for 5-HT3 receptors (i.e., 5-HT3 receptor Ki = 6,200 nM) 
and higher potency at α7 nACh receptors (i.e., IC50 = 1.26 µM), examined using patch-clamp 
technique on rat α7 nAChRs expressed in HEK cells, compared to MD-354 (20) (i.e., 5-HT3 
receptor Ki = 35 nM; IC50 = 7.98 µM). 
Previous molecular modeling studies9 indicated possible different binding modes between 
MD-354 (20) and its N-methyl analog 24, which prompted us to investigate the structural 
requirements for the action of arylguanidines at α7 nAChRs. One of the aims of this project was 
!
!
!
!
116!
to study the SAR and determine the optimal structural features of arylguanidines for inhibiting 
ACh responses at α7 nACh receptors. Figure 38 summarizes the three main structural regions 
that were investigated for optimizing arylguanidine inhibitory action.  
 
Two series of compounds were prepared, based on 20 and 24, to explore the aryl 3-position, 
to test the effect of substituent size, lipophilic nature, and a different range of electronic effects 
and to test a possible change in pharmacological profile of the new molecules. The structural 
modifications included H, F, Cl, Br, I, CF3, OCH3, and CH3. Biological potencies of the MD-354 
series and the N-methyl series of compounds, obtained from electrophysiological assays with 
Xenopus laevis oocytes expressing human α7 nAChRs using a two-electrode voltage-clamp 
assay, showed IC50 values ranging from 12 – 125 µM. Among those compounds, N-(3-
iodophenyl)-N-methylguanidine (28) was the most potent inhibitor of ACh responses at α7 nACh 
1 
2 
3 
N
R
NH2
NH
Cl
Figure 38. Representation of the three main structural components of arylguanidines 
investigated in this study. 
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receptors. A poor correlation (r = 0.474; n = 8) of pIC50 values of the 20 series versus pIC50 
values of the 24 series supported our docking results suggesting that the two series bind 
differently. Hansch-type QSAR studies were conducted using several physicochemical properties 
to determine the effect of similar modifications in the two series on NAM activity. Data for the 
24 (i.e., N-CH3) series showed a significant correlation with the minimum width (Verloop B1) (r 
= 0.927; n = 8) and lipophilic nature (π) (r = 0.912; n = 8) of the 3-position substituent. 
However, a significant internal correlation exists between the two properties (r = 0.956; n = 8). 
Consequently, additional analogs will be required to resolve this issue.176 Nevertheless, the effect 
of the parallel structural modifications at α7 nAChRs and Hansch analyses indicate different 
binding modes for the two series.  
 The Topliss operational scheme135 for the aliphatic side chain was used to optimize 
pharmacological activities associated with the alkyl group at the anilinic nitrogen atom of the 
arylguanidines at α7 nAChRs. According to the approach, replacement of the N-methyl group in 
24 with an N-isopropyl group should increase its π effect.135 A total of four pairs of compounds 
were initially examined at which the effect of the chloro group was also investigated through 
deschloro compounds. Introduction of isopropyl groups was examined. The findings indicate that 
the N1-iPr group (i.e., increased lipophilicity) appears to increase NAM potency, especially with 
deschloro analogs where more pronounced effects are detected. 
We also studied the role of the guanidine nitrogen atoms on the inhibitory effects of 
arylguanidines at α7 nAChRs. The effect of alkylating one or more of the guanidine nitrogen 
atoms, and the necessity of the presence of these nitrogen atoms for their NAM action, and/or 
action as an α7 nAChR antagonist was investigated, because these structural changes are known 
to be detrimental to 5-HT3 receptor binding. The results appear to support the concept that 
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alkylation of the nitrogen atoms is well tolerated and that not all of the nitrogen atoms are 
required for α7 nAChR antagonist action. However, more pharmacological studies are needed to 
confirm this observation. 
Molecular modeling studies were conducted to identify the potential binding site(s) as well as 
the mode of interactions of arylguanidines at α7 nAChRs. Eight potential allosteric binding 
cavities were initially identified, but only two of them, one at the extracellular domain (ECD) 
and the other at the transmembrane domain (TMD), appeared to be reasonable binding sites for 
our α7 nAChR allosteric modulators. Docking studies resulted in different binding modes for 20 
and 24. HINT analyses were performed on the two binding sites and an energetic preference was 
found for the interaction of 20 and 24 at the ECD allosteric site over the TMD site. These results 
indicated that small-molecule arylguanidine NAMs (although the 20 and 24 series could bind 
somewhat differently) might interact at the same binding site as PAMs at α7 nACh receptors. 
A pharmacophore model for arylguanidine NAMs at α7 nACh receptors has not been 
investigated previously. We initiated the first attempt to identify a pharmacophore model of 
small-molecule arylguanidine NAMs of α7 nAChRs. Our pharmacophore studies showed a low 
likelihood of a common pharmacophore model for all arylguanidine NAMs which supported the 
possibility of different binding modes between the NH guanidines and the N-alkylated 
guanidines. The first pharmacophore model of N-alkyl arylguanidines at α7 nAChRs was 
proposed. Newly synthesized compounds will be subsequently used to evaluate the predictability 
of the model, however, there might be a need for more compounds and a wider range of IC50 
values in order to have better predictability. 
Overall, three main regions in the arylguanidines were studied for their influence on 
NAM action at α7 nAChRs. Multiple medicinal chemistry approaches were employed to 
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rationally design novel α7 nAChR NAMs. We succeeded in improving the selectivity as well as 
the potency of the parent compound MD-354 (20) toward α7 nAChRs. In addition, we have 
constructed models of the ECD and the TMD of α7 nAChRs, energetically assessed binding at 
the potential allosteric sites, and studied the plausible binding modes that might explain the 
actions of our compounds. The study led to the 24 series of compounds and the N1-isopropyl 
arylguanidine compounds that opened an investigation window to a number of compounds that 
could guide us to promising novel α7 nAChR small-molecule NAMs.  
Marijuana addiction, especially with the increasing legalization for medicinal and non-
medicinal use, increases the necessity to open a new approach for treatment of their abuse. For 
medicinal chemists as well as other researchers in the drug discovery field, it is required to 
investigate possible ways to fight diseases such as AD, depression and cognitive dysfunction. 
Here, α7 nAChR-selective antagonists might represent a valuable pathway for promising 
therapeutic strategy. Small-molecule NAMs (arylguanidines), because they offer an alternative to 
orthosteric α7 nAChR antagonists, might represent a novel class of compounds with potential 
therapeutic value.  
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VI. Experimental 
 
 
 
A. Synthesis  
 
Melting points (mp) were taken in glass capillary tubes using a Thomas-Hoover melting 
point apparatus and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra were 
obtained using a Bruker ARX 400 MHz spectrometer at which peak positions are given in parts 
per million (δ) downfield from the internal standard tetramethylsilane (TMS), followed by the 
splitting pattern (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = 
multiplet), coupling constant (Hz), and integration. Infrared spectra were obtained on a Thermo 
Nicolet iS10 FT-IR. Purity of compounds was determined by elemental analysis performed by 
Atlantic Microlab Inc. (Norcross, GA) for the indicated elements, and the obtained values are 
within 0.4% of theoretical values. Reactions were monitored by thin-layer chromatography 
(TLC) on silica gel GHLF plates (250 µm, 2.5 X 10 cm; Analtech Inc. Newark, DE), and Flash 
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc. Lincoln, 
NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase 
Silica Flash Column, Teledyne Isco Inc., Lincoln, NE).  Electrospray ionization-mass 
spectroscopy (ESI-MS) profiles were recorded using a Waters Acquity TQD (tandem 
quadrupole) spectrometer in positive ion mode.  
!
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N-Methyl-3-trifluoromethylaniline Nitrate (37). N-Methyl-3-trifluoromethylaniline nitrate 
(37) was prepared according to a literature procedure for a similar compound.151 Cyanamide (0.7 
g, 17.9 mmol) was added to a solution of N-methyl-3-trifluoromethylaniline hydrochloride (47) 
(1.9 g, 8.9 mmol) in absolute EtOH (20 mL). The stirred reaction mixture was heated at reflux 
for 24 h. Upon cooling, the reaction mixture was concentrated under reduced pressure to yield a 
residue that was recrystallized from 1-butanol to give 4.8 g (21%) of the desired product as white 
crystals: mp 247-249 °C; IR (diamond, cm-1): 3120 (NH), 3282 (NH2); 1H NMR (DMSO-d6) δ 
3.29 (s, 3H, CH3), 7.72 (m, 2H, ArH), 7.79 (d, J = 7.68 Hz, 1H, ArH), 7.82 (s, 1H, ArH). Anal. 
Calcd (C9H10F3N3·HCl) C, 42.62; H, 4.37; N, 16.57.  Found: C, 42.66; H, 4.30; N, 16.52. 
N-Isopropyl-N-phenylguanidine Nitrate (38). N-Isopropyl-N-phenylguanidine nitrate (38) was 
prepared according to a literature procedure.152 An aqueous solution of cyanamide (50%; 1.5 
mL) was added to a solution of N-isopropylaniline hydrochloride (48) (100 mg, 0.58 mmol) in 
absolute EtOH (9 mL). The stirred reaction mixture was heated at reflux for 25 h, and then 
cooled to 0 °C (freezer) for 20 h. The solvent was removed under reduced pressure, the resulting 
oily residue was dissolved in H2O (1 mL) followed by addition of NH4NO3 (108 mg, 1.34 
mmol). The solution was concentrated under reduced pressure and the residue was dissolved in 
H2O (5 mL), washed with Et2O (3 x 20 mL), followed by evaporation of H2O under reduced 
pressure. The resulting solid was recrystallized from H2O and, then, from absolute EtOH to give 
30 mg (21%) of the desired product as white crystals: mp 164-165 °C; IR (Diamond) cm-1: 2159, 
3172 (NH), 3319 (NH2); 1H NMR (DMSO-d6): δ 1.05 (d, J = 6.52 Hz, 6H, CH3), 4.4 (m, 1H, 
CH), 7.3 (m, 2H, ArH), 7.6 (m, 3H, ArH). Anal. Calcd (C10H15N3·HNO3) C, 49.99; H, 6.71; N, 
23.32.  Found: C, 49.85; H, 6.64; N, 23.27. 
!
!
!
!
122!
N-(3-Chlorophenyl)-N-isopropylguanidine Hydrochloride (39). N-(3-Chlorophenyl)-N-
isopropylguanidine hydrochloride (39) was prepared using a literature procedure for a similar 
compound.151 Cyanamide (1.02 g, 24.26 mmol) was added to a solution of 3-chloro-N-
isopropylaniline (51) (2.50 g, 12.13 mmol) in absolute EtOH (30 mL). The reaction mixture was 
allowed to stir at reflux for 24 h. The solution was concentrated under reduced pressure and 
anhydrous Et2O (25 mL) was added. The white precipitate was collected by filtration and 
recrystallized from i-PrOH to give 0.51 g (17%) of the desired product as white crystals: mp 
272-274 °C; IR (diamond, cm-1): 3108 (NH), 3269 (NH2); 1H NMR (DMSO-d6) δ: 1.04 (d, J = 
6.56 Hz, 6H, CH3), 4.36 (m, 1H, CH), 7.28 (td, J = 7.72, 1.62 Hz, 1H, ArH), 7.45 (t, J = 1.84 Hz, 
1H, ArH), 7.58 (m, 2H, ArH). Anal. Calcd (C10H14ClN3·HCl) C, 48.40; H, 6.09; N, 16.93.  
Found: C, 48.68; H, 6.11; N, 17.06. 
N,N'-Di(3-trifluoromethylphenyl)urea (45). N,N'-Di(3-trifluoromethylphenyl)urea (45) was 
accidently prepared using a patent procedure for the synthesis of carbamate compounds.178
 
Triethylamine was added to a solution of 3-trifluoromethylaniline (3.8 g, 23.6 mmol) in 
anhydrous Et2O (10 mL). A solution of ethyl chloroformate (2.5 g, 23.6 mmol) in anhydrous 
Et2O (5 mL) was added in a dropwise manner at 0 °C (ice-bath), and the stirred reaction mixture 
was allowed to stir for 1 h at room temperature. The solid was collected by filtration and washed 
with DCM to yield 0.7 g (18%) of 45 as a white crystals: mp 190-192 °C (179lit. mp 198 °C, 
DMF/H2O); IR (diamond, cm-1): 1702 (CO), 3302 (NH); 1H NMR (DMSO-d6) δ 7.34 (d, J = 
7.64 Hz, 2H, ArH), 7.53 (t, J = 7.80 Hz, 2H, ArH), 7.62 (d, J = 8.52 Hz, 2H, ArH), 8.01 (s, 2H, 
ArH). 
Ethyl N-[3-(trifluoromethyl)phenyl] carbamate (46). Ethyl N-[3-(trifluoromethyl)phenyl] 
carbamate (46) was prepared according to a literature procedure.149 Sodium hydride 60% in 
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mineral oil (0.5 g, 23.6 mmol) was washed with anhydrous toluene (2 × 5 mL) under an N2 
atmosphere to remove the oil. The obtained solid was dissolved in anhydrous THF (10 mL) and a 
solution of 3-trifluoromethylaniline (3.8 g, 23.6 mmol) in anhydrous THF (10 mL) was added. A 
solution of ethyl chloroformate (2.5 g, 23.6 mmol) in anhydrous THF (5 mL) was added in a 
dropwise manner at 0 °C (ice-bath), and the stirred reaction mixture was allowed to stir for 1.5 h 
at room temperature. The mixture was filtered and the filtrate was concentrated under reduced 
pressure and dried under high vacuum to yield 4.8 g (88%) of 46 as a yellow oil: IR (diamond, 
cm-1): 1707 (CO), 3381 (NH); 1H NMR (DMSO-d6) δ 1.34 (t, J = 7.10 Hz, 3H, CH3), 2.71 (q, J 
= 7.12 Hz, 2H, CH2), 7.36 (d, J = 7.76 Hz, 1H, ArH), 7.44 (t, J = 8.0 Hz, 1H, ArH), 7.57 (d, J = 
8.36 Hz, 1H, ArH), 7.72 (s, 1H, ArH). The product was used without further characterization in 
the preparation of 47. 
N-Methyl-3-trifluoromethylaniline Hydrochloride (47). N-Methyl-3-trifluoromethylaniline 
hydrochloride (47) was prepared according to a literature procedure.150 A solution of ethyl N-[3-
(trifluoromethyl)phenyl] carbamate (46) (5.0 g, 31.0 mmol) in anhydrous THF (15 mL) was 
added in a dropwise manner to a stirred suspension of LiAlH4 (2.4 g, 64.3 mmol) in anhydrous 
THF (15 mL) at 0 °C (ice-bath) under an N2 atmosphere. The reaction mixture was heated at 
reflux overnight. Excess of LiAlH4 was decomposed by addition of H2O (2.5 mL), NaOH (2.5 
mL, 15%), and H2O (7.5 mL), slowly and in a dropwise manner, and the mixture was allowed to 
stir for 0.5 h. The reaction mixture was filtered and the collected solid was washed with hot THF 
(10 mL). The filtrate was dried (MgSO4), solvent was removed under reduced pressure and dried 
under high vacuum to yield 1.7 g of the free base of 47 as a yellow oil. The free base was 
dissolved in Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate 
was collected by filtration and recrystallized from a mixture of absolute EtOH/Et2O to give 1.9 g 
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(44%) of the product as white crystals: mp 108-110 °C; IR (diamond, cm-1): 1453, 2638 (NH); 
1H NMR (DMSO-d6) δ 2.73 (s, 3H, CH3), 6.89 (m, 2H, ArH), 7.33 (m, 2H, ArH). 
3-Chloro-N-isopropylaniline Hydrochloride (51). 3-Chloro-N-isopropylaniline hydrochloride 
(51) was prepared according to a literature procedure.153 A mixture of 3-chloroaniline (49) (1.00 
g, 7.83 mmol) and 2-bromopropane (50) (0.48 g, 3.92 mmol) was heated to 150 °C. Then, the 
reaction mixture was allowed to cool to room temperature and washed with an aqueous solution 
of NaOH (15%, 10 mL). The oily residue was shaken with an aqueous solution of ZnCl2 (10%, 
10 mL). Excess ZnCl2 solution was decanted and the obtained residue was extracted with 
petroleum ether (4×10 mL). The solvent was removed under reduced pressure and the residue 
was purified by flash chromatography (silica gel; hexane/EtOAc; 9:1). The obtained oil was 
dried under high vacuum for 6 h to yield 0.6 g (45%) of the free base of 51 as a yellow oil. The 
free base was dissolved in Et2O and a saturated solution of HCl in anhydrous Et2O (50 mL) was 
added. The precipitate was collected by filtration and recrystallized from a mixture of absolute 
EtOH/Et2O to give 0.71 g of the desired product as white crystals: mp 238-239 °C; IR (diamond, 
cm-1): 1594, 3044 (NH); 1H NMR (DMSO-d6) δ: 1.5 (d, J = 6.28 Hz, 6H, CH3), 3.52 (septet, J = 
6.35 Hz, 1H, CH), 6.43 (d, J = 8.12 Hz, 1H, ArH), 6.54 (s, 1H, ArH), 6.59 (d, J = 7.84 Hz, 1H, 
ArH), 7.0 (t, J = 8.02 Hz, 1H, ArH). The product was used without further characterization for 
synthesis of compound 39. 
N-Ethyl-N-phenylguanidine Hydrochloride (52). N-Ethyl-N-phenylguanidine hydrochloride 
(52) was prepared according to a literature procedure.154 Cyanamide (299 mg, 7.10 mmol) was 
added to a solution of N-ethylaniline hydrochloride (54) (800 mg, 5.09 mmol) in 1-pentanol (15 
mL). The stirred reaction mixture was heated at reflux for 24 h. Upon cooling, the reaction 
mixture was concentrated under reduced pressure to obtain an oily residue that was crystallized 
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from a mixture of absolute EtOH/Et2O to give 209 mg (21%) of the desired product as off-white 
crystals: mp 175-177 °C (154lit. mp 185 °C, EtOH/Et2O); IR (diamond, cm-1): 2977, 3189 (NH), 
3303 (NH2); 
1H NMR (DMSO-d6) δ: 1.10 (t, J = 7.12 Hz, 3H, CH3), 3.66 (q, J = 7.12, 7.14 Hz, 
2H, CH2), 7.35 (d, J = 7.08 Hz, 2H, ArH), 7.47 (t, J = 7.34 Hz, 1H, ArH), 7.54 (t, J = 7.36 Hz, 
2H, ArH). 
N-(3-Chlorophenyl)-N-ethylguanidine Hydrochloride (53). N-(3-Chlorophenyl)-N-
ethylguanidine hydrochloride (53) was prepared using a literature procedure for a similar 
compound.151
 
Cyanamide (0.13 g, 3.12 mmol) was added to a solution of 3-chloro-N-ethylaniline 
hydrochloride (55) (0.3 g, 1.56 mmol) in absolute EtOH (10 mL). The stirred reaction mixture 
was heated at reflux for 24 h. Upon cooling, the reaction mixture was concentrated under 
reduced pressure to obtain a residue that was recrystallized from a mixture of absolute 
EtOH/Et2O to give 0.048 g (13%) of the desired product as white crystals: mp 186-189 °C; IR 
(diamond, cm-1): 3077, 3187 (NH), 3274 (NH2); 
1H NMR (DMSO-d6) δ: 1.07 (t, J = 7.16 Hz, 
3H, CH3) 3.66 (q, J = 7.12, 7.16 Hz, 2H, CH2), 7.34 (m, 1H, ArH), 7.54 (m, 3H, ArH). Anal. 
Calcd (C9H12ClN3·HCl) C, 46.17; H, 5.60; N, 17.95.  Found: C, 45.93; H, 5.64; N, 17.72. 
3-Chloro-N-ethylaniline Hydrochloride (55). 3-Chloro-N-ethylaniline hydrochloride (55) was 
prepared according to a literature procedure.155
 
Acetaldehyde (1.5 mL, 27.0 mmol), 3-
chloroaniline (49) (3.4 g, 27.0 mmol), and pyridine-borane (1.9 mL, 22.5 mmol) were 
sequentially added to a methanol solution (120 mL) containing powdered 4 Å molecular sieves 
(2.4 g) under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 24 h. Upon 
cooling to room temperature, the mixture was filtered through a small bed of Celite (Hyflo 
Super-Cel®) and the filtrate was collected. This filtrate was concentrated under reduced pressure 
to give an oily residue. The residue was purified by flash chromatography (silica gel; 
!
!
!
!
126!
hexane/EtOAc; 9:1) to obtain a solution that was concentrated under reduced pressure and dried 
under vacuum for 14 h to yield 0.6 g of the free base of 55 as a yellow oil. The free base was 
dissolved in Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate 
was collected by filtration and recrystallized from a mixture of absolute EtOH/Et2O to give 0.7 g 
(12%) of the product as white crystals: mp 144-146 °C; IR (diamond, cm-1): 1587, 2650 (NH); 
1H NMR (DMSO-d6) δ: 1.20 (t, J = 7.16, 7.20 Hz, 2H, CH2), 7.13 (d, J = 4.92 Hz, 2H, ArH), 
7.24 (s, 1H, ArH), 7.37 (t, J = 4.16 Hz, 1H, ArH). The product was used without further 
characterization for synthesis of compound 53.  
N-(3-Cyanophenyl)-N-methylguanidine Nitrate (56). N-(3-Cyanophenyl)-N-methylguanidine 
nitrate (56) was prepared using a literature procedure for a similar compound.151 Cyanamide 
(0.25 g, 6.0 mmol) was added to a solution of 3-(methylamino)benzonitrile  hydrochloride (59) 
(0.5 g, 3.0 mmol) in absolute EtOH (15 mL). The stirred reaction mixture was heated at reflux 
for 24 h. Upon cooling the reaction mixture, the solvent was evaporated under reduced pressure 
and the obtained residue was dissolved in H2O (8 mL), followed by addition of NH4NO3 (0.29 g, 
3.62 mmol). The solvent was evaporated under reduced pressure and the resultant semisolid was 
recrystallized from EtOAc to give 0.13 g (19%) of the desired product as white crystals: mp 117-
119 °C; IR (diamond, cm-1): 2803, 3039 (NH), 3123 (NH2); 
1H NMR (DMSO-d6) δ: 3.28 (s, 3H, 
CH3), 7.74 (m, 2H, ArH), 7.89 (d, J = 7.48 Hz, 1H, ArH), 7.98 (s, 1H, ArH). Anal. Calcd 
(C9H10N4·HNO3) C, 45.57; H, 4.67; N, 29.52.  Found: C, 45.87; H, 4.68; N, 29.17; LRMS (ESI) 
calculated for C9H11N4, [M + H]+, m/z 175.0905, found m/z 174.8022. 
N-Cyclopentyl-N-phenylguanidine Hydrochloride (57). N-Cyclopentyl-N-phenylguanidine 
hydrochloride (57) was prepared using a literature procedure for a similar compound.151 
Cyanamide (0.64 g, 15.17 mmol) was added to a solution of N-cyclopentylaniline hydrochloride 
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(62) (1.5 g, 7.58 mmol) in absolute EtOH (15 mL). The stirred reaction mixture was heated at 
reflux for 24 h. Upon cooling, the solvent was evaporated under reduced pressure to obtain a 
residue that was washed with cyclohexane and recrystallized from THF to give 0.15 g (9%) of 
the desired product as white crystals: mp 209-211 °C; IR (diamond, cm-1): 2956, 3117 (NH), 
3276 (NH2); 
1H NMR (DMSO-d6) δ: 1.20 (m, 2H, CH2), 1.43 (m, 4H, CH2), 1.92 (m, 2H, CH2), 
4.31 (m, 1H, CH), 7.28 (m, 2H, ArH), 7.53 (m, 3H, ArH). Anal. Calcd (C9H12ClN3·HCl·0.1 
C6H12) C, 65.94; H, 9.06; N, 13.44.  Found: C, 65.98; H, 9.13; N, 13.15. 
N-(3-Chlorophenyl)-N-cyclopentylguanidine Nitrate (58). N-(3-Chlorophenyl)-N-
cyclopentylguanidine nitrate (58) was prepared using a literature procedure for a similar 
compound.151
 
Cyanamide (0.72 g, 17.23 mmol) was added to a solution of 3-chloro-N-
cyclopentylaniline hydrochloride (63) (2.0 g, 8.61 mmol) in absolute EtOH (15 mL). The stirred 
reaction mixture was heated at reflux for 24 h. The solution was concentrated under reduced 
pressure and was dissolved in H2O (8 mL). The solution was washed with Et2O (3 x 20 mL), 
followed by evaporation of H2O under reduced pressure. The resultant oily residue was dissolved 
in H2O (8 mL), followed by addition of NH4NO3 (0.12 g, 1.44 mmol). The solvent was 
evaporated under reduced pressure and the resultant semisolid was recrystallized from EtOH to 
give 0.34 g (15%) of the desired product as white crystals: mp 225-227 °C; IR (diamond, cm-1): 
2969, 3175 (NH), 3346 (NH2); 
1H NMR (DMSO-d6) δ: 1.19 (m, 2H, CH2), 1.45 (m, 4H, CH2), 
1.94 (m, 2H, CH2), 4.27 (m, 1H, CH), 7.29 (dd, J = 1.64, 7.52 Hz, 1H, ArH), 7.48 (s, 1H, ArH), 
7.55 (m, 2H, ArH). Anal. Calcd (C12H16ClN3·HNO3) C, 47.93; H, 5.70; N, 18.63.  Found: C, 
48.06; H, 5.59; N, 18.61. 
N-Cyclopentylaniline Hydrochloride (62). N-Cyclopentylaniline was synthesized according to 
a patent procedure.180 Cyclopentanone (61) (3.8 mL, 43.0 mmol), acetic acid (1.2 mL, 21.5 
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mmol), and sodium triacetoxyborohydride (9.1 g, 43.0 mmol) were added to a solution of aniline 
(60) (2.0 mL, 21.5 mmol) in dichloromethane (15 mL) and the reaction mixture was allowed to 
stir at room temperature for 1.5 h. The mixture was washed with saturated aqueous sodium 
bicarbonate solution (3 × 25 mL) and the solvent was evaporated under reduced pressure, dried 
under vacuum for 14 h to yield 4.0 g of the free base of 62 as yellow oil. The free base was 
dissolved in anhydrous Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The 
precipitate was collected by filtration and recrystallized from EtOAc to give 3.1 g (89%) of the 
product as white crystals: mp 149-151 °C; IR (diamond, cm-1): 1584, 2631 (NH); 1H NMR 
(DMSO-d6) δ: 1.55 (m, 2H, CH2), 1.77 (m, 4H, CH2), 1.85 (m, 2H, CH2), 3.88 (m, 1H, CH), 7.41 
(m, 1H, ArH), 7.52 (m, 4H, ArH). The product was used without further characterization for 
synthesis of compound 59. 
3-Chloro-N-cyclopentylaniline Hydrochloride (63). 3-Chloro-N-cyclopentylaniline 
hydrochloride (63) was synthesized according to a patent procedure for a similar compound.180 
Cyclopentanone (61) (2.8 mL, 31.35 mmol), acetic acid (0.6 mL, 15.68 mmol), and sodium 
triacetoxyborohydride (6.6 g, 31.35 mmol) were added to a solution of 3-chloroaniline (49) (1.6 
mL, 15.68 mmol) in dichloromethane (15 mL) and the reaction mixture was allowed to stir at 
room temperature for 1.5 h. The mixture was washed with saturated aqueous sodium bicarbonate 
solution (3 × 25 mL) and the solvent was evaporated under reduced pressure and dried under 
vacuum for 7 h to yield 2.7 g of the free base of 63 as yellow oil. The free base was dissolved in 
Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate was collected 
by filtration and recrystallized from EtOAc to give 3.0 g (98%) of the product as white crystals: 
mp 115-117 °C; IR (diamond, cm-1): 1589, 2628 (NH); 1H NMR (DMSO-d6) δ: 1.58 (m, 4H, 
CH2), 1.72 (m, 2H, CH2), 1.88 (m, 2H, CH2), 3.78 (m, 1H, CH), 7.01 (m, 3H, ArH), 7.27 (m, 1H, 
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ArH). The product was used without further characterization for synthesis of compound 58. 
 
B. Electrophysiology  
Xenopus oocytes: (studies were conducted by Shailesh Khatri, a graduate student in Dr. Schulte’s 
Laboratory) 
“Arylguanidine analogs were evaluated functionally using two-electrode voltage clamp of 
human α7 nACh receptors expressed in Xenopus oocytes using previously published 
procedures.181 Four independent recording stations with integral autosampling and data collection 
were available for this study. 
The chimeric DNAs (cDNA) for human α7 receptors were obtained from Dr. Jon 
Lindstrom’s Laboratory (Department of Neuroscience, School of medicine, University of 
Pennsylvania). cDNA was cloned into a pBud-CE4.1 (Invitrogen, CA) vector prior to RNA 
synthesis.  
Ovarian lobes were surgically removed from X. laevis frogs and washed twice in Ca2+ free 
Barth’s buffer [82.5 mM NaCl/2.5mM KCl/1 mM MgCl2/5 mM HEPES, pH 7.4]. Lobes were 
gently shaken with 1.5mg/ml collagenase (Sigma type II, Sigma–Aldrich) for 20-30 minutes at 
room temperature. Stage IV oocytes were selected for microinjection. Synthetic cRNAs for wild 
type human α7 were prepared using the mMESSAGE mMACHINETM High Yield Capped RNA 
Transcription Kit (Ambion, TX). Each oocyte was injected with 50 nl cRNA at a concentration 
of 300 ng/µl. Oocytes were incubated at 19 °C for 36-48 hours before electrophysiological 
experiments. Electrical recordings were made using automated two-electrode voltage clamp at –
60 mV employing an OC-725C oocyte clamp amplifier (Warner Instruments, CT, US) coupled 
to an online, computerized data acquisition system (pCLAMP, Molecular Devices, LLC, USA) 
along with auto injection system (Gilson). 
Recording and current electrodes were filled with 3 M KCl and had resistances of 1–4 MΩ. 
Oocytes were held in a vertical flow chamber of 200-280µl volumes and perfused with ND-96 
recording buffer (96 mM NaCl/2 mM KCl/1.8 mM CaCl2/1 mM MgCl2/5 mM HEPES, pH 7.4) 
at a rate of 20 ml/min. Details of chamber and methodology employed for two electrode voltage 
clamp recordings have been described earlier (Joshi et al., 2004). All agonists (Acetylcholine) 
and antagonists (Analogs in test) were prepared in ND-96 buffer. Antagonists were co-applied 
with 100µM acetylcholine (ACh) to record inhibition of ACh evoked currents by antagonist. 
Dose–response curves obtained from electrophysiological data were fit using the equation I = 
Imax/(1 + EC50/[A]n), where I is the current at a given agonist concentration, Imax is the 
maximal current, EC50 is the agonist concentration that elicits a half-maximal current, and n is 
the Hill coefficient. Ki were calculated using Cheng-Prusoff equation. All the analysis of the data 
was done using GraphPad PRISM. Quantative data were expressed as mean ± S.E. Association 
between the variables, where need, were tested by using paired students t test. All statistical 
differences were deemed significant at the level of P<0.05.”182 
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HEK 293 cells: (studies were conducted by Dr. Galya Abdrakhmanova) 
“Stably transfected HEK 293 cells expressing rat α7 nAChRs were prepared as described 
previously.183-185 All three cell lines were maintained at 37 °C with 5% CO2 in the incubator. 
Growth medium for HEK 293 cells was minimum essential medium supplemented with 10% 
fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. The stably transfected cell 
line was raised in selective growth medium containing 0.7 mg/ml of geneticin (Invitrogen Corp, 
Carlsbad, CA). Growth medium for SH-EP1 cells was Dulbecco’s Modified Eagle’s medium 
with high glucose supplemented with 10% heat inactivated horse serum, 5% fetal bovine serum, 
100 U/ml penicillin, 100 mg/ml streptomycin, 8 mM L-glutamine, 1 mM sodium pyruvate, and 
0.25 mg/ml amphotericin (all from Invitrogen Corp, Carlsbad, CA). This stably transfected cell 
line was raised in selective medium containing 0.5 mg/ml zeocin (Invitrogen) and 0.4 mg/ml 
hygromycin B (Roche Diagnostics Corp, Indianapolis, IN).”186 
“Functional expression of nAChRs was evaluated in the whole-cell configuration of the 
patch-clamp technique using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, 
USA). The patch electrodes, pulled from borosilicate glass capillaries (Sutter Instrument 
Company, Novato, CA, USA), had a resistance of 2.5–3.5 MΩ when filled with an internal 
solution containing 110 mM Tris phosphate dibasic buffer, 28 mM Tris base, 11 mM EGTA, 2 
mM MgCl2, 0.1 mM CaCl2, and 4 mM Mg-ATP (pH adjusted to 7.3 with Tris base).187,188 In 
some cells, ~85% of electrode resistance was compensated electronically, so that the effective 
series resistance in the whole-cell configuration was accepted when less than 20 MΩ. Stably 
transfected HEK cells were studied for 2–3 days after plating the cells on 15-mm round plastic 
cover slips (Thermanox, Nalge Nunc, Napierville, IL, USA). Generation of voltage-clamp 
protocols and acquisition of the data were carried out using pCLAMP 9.0 software (Molecular 
Devices). Sampling frequency was 5 kHz and current signals were filtered at 5 or 10 kHz before 
digitization and storage. All experiments were performed at room temperature (22–25 °C).  
 
Cells plated on cover slips were transferred to an experimental chamber mounted on the stage 
of an inverted microscope (Olympus IX50, Olympus Corporation, Tokyo, Japan) and were 
bathed in a solution containing 140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 25 mM D-glucose, 10 
mM HEPES, and 2 mM CaCl2 (pH adjusted to 7.4 with Tris base). The experimental chamber 
was constantly perfused with control bathing solution (1–2 ml/min). The high-speed solution 
exchange system, HSSE-2 (ALA Scientific Instruments, Westbury, NY, USA), was used to 
deliver control and test solutions. Under optimal conditions, the delay in switching between 
solutions was ~10 ms. Data presented herein were obtained through subtraction from the leak 
current.”8  
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C. MolecularModeling  
 
The primary sequence of the human α7 nACh receptor was acquired from the Universal 
Protein Resource (UniProt) (entry code: P36544; Homo sapiens). Multiple alignments of the hα7 
nAChR sequence were performed with several orthologs by ClustalX 2.0137 using the following 
UniProtKB accession codes: Q05941 (rat α7 nAChR; Rattus norvegicus), P22770 (chicken α7 
nAChR; Gallus gallus). Homology models of the ECD and TMD of human α7 nAChRs were 
generated using Modeller 9.12 (Version 9.12; University of California San Francisco, San 
Francisco, CA) based on three templates: the X-ray crystal structure of a chimeric ECD of the α7 
nACh receptor (PDB ID 3SQ9)70 that shares 64% sequence identity with the ECD of the human 
α7 nACh receptor subunit, the NMR structure for the TMD of the α4 nAChR subunit (PDB ID 
2LLY)74 that shares 49% sequence identity with the TMD of the human α7 nAChR subunit, and 
the cryo-electron microscopic structure of the Torpedo marmorata nAChR (PDB ID 2BG9)21 
that shares 53% sequence identity with the TMD of the human α7 nAChR subunit. All the 
template structures were retrieved from the PDB Data Bank at http://www.rcsb.org. The 
resulting models of each domain were evaluated based on the discrete optimized protein energy 
(DOPE) and the molecular probability density function (Molpdf) scores and validated by the 
docking of α7 nACh receptor modulators (i.e., galantamine for ECD, PNU-120596 and 
ivermectin for TMD). A cavity-search study was conducted based on the Connolly surface 
feature of SYBYL-X 2.1 (Tripos Inc. St. Louis, MO) and the blind docking approach within 
AutoDock (Version 4.2; Scripps Research Institute, La Jolla, CA). The empirical data from two 
α7 nACh receptor PAMs (i.e., ivermectin, PNU-120596) were used as a guiding tool in plausible 
binding site exploration. 
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Four low-energy rotamers of N-methyl mCPG were computationally prepared using SYBYL-
X 2.1. Molecular docking was conducted using the CHEMPLP scoring function within the 
genetic algorithm docking program GOLD (Version 5.2; Cambridge Crystallographic Data 
Centre, Cambridge, UK),175 and the docking solutions were analyzed (SYBYL-X 2.1). The 
binding site was defined to include all atoms within 10 Å of the α-carbon atom of the key amino 
acid residue for the candidate homology models. Based on the fitness scores and the binding 
orientation of each ligand within the binding cavity, the best-docked solution was selected and 
merged into the receptor. The initial models were energetically optimized using the Tripos Force 
Field (Gasteiger–Hückel charges, distance-dependent dielectric constant = 4.0) to optimize the 
interactions between ligand and receptor within the binding pocket, followed by PROCHECK 
and ProTable analyses to validate the candidate models. These optimized model-ligand 
complexes were then rescored with HINT (Hydropathic INTeractions) program;141 an empirical 
scoring function based on the experimental free energy information derived from log Po/w (the 
solvent partition coefficient for 1-octanol/water). 
In the pharmacophore determination study, the compounds were aligned using GASP with 
modifications in the default parameter. The population size (i.e., alignment solutions 
conformations) was set to 125, the allele mutate weight (i.e., conformation diversity) to 96, and 
the fitness increment (i.e., superimposition criteria) to 0.02. CoMFA calculations were conducted 
using the QSAR module of SYBYL-X 2.1. The standard setting of 30 kcal/mol as energetic cut-
off value was used. Regression analyses were performed using the SYBYL-X 2.1 tool of the 
partial least square (PLS) algorithm with cross-validation (leave-one-out) and optimum number 
of components.  
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Concentration/response curves for compounds included in this study. 
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Figure A1. Concentration/response curves for arylguanidines 21-23, 25-34, 37-39, 52, 
and 53 (A-R) inhibition of peak currents elicited by 100 µM ACh at α7 nAChRs. 
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Appendix B 
 
 
Primary QSAR analyses for the N-methyl series compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
Figure B1. Plot of pIC50 values of the N-methyl analog series versus the electronic 
character (σm) (r = 0.453, p = 0.260, n = 8).  
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Figure B2. Plot of pIC50 values of the N-methyl analog series versus Verloop length (L) 
(r = 0.763, p = 0.030, n = 8).  
Figure B3. Plot of pIC50 values of the N-methyl analog series versus Verloop maximum 
width (B5) (r = 0.448, p = 0.265, n = 8).  
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Figure B4. Plot of pIC50 values of the N-methyl analog series versus the molar 
refraction (MR) (r = 0.875, p = 0.021, n = 8).  
Figure B5. Plot of pIC50 values of the N-methyl analog series versus the solvent 
accessibility volume (Vol) (r = 0.882, p = 0.013, n = 8).  
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Figure B6. Plot of pIC50 values of the N-methyl analog series versus the number of 
valence electron (NVE) (r = 0.263, p = 0.528, n = 8).  
Figure B7. Plot of pIC50 values of the N-methyl analog series versus the complete molar 
refraction (CMR) (r = 0.893, p = 0.122, n = 8).  
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Figure B8. Plot of pIC50 values of the N-methyl analog series versus the molar volume 
(MV) (r = 0.540, p = 0.166, n = 8).  
Figure B9. Plot of pIC50 values of the N-methyl analog series versus Parachor values 
(Pc) (r = 0.805, p = 0.023, n = 8).  
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Figure B10. Plot of pIC50 values of the N-methyl analog series versus the polarizability 
of the compounds (r = 0.890, p = 0.016, n = 8).  
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